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Estrogen, acting via estrogen receptor α (ERα), stimulates cancer cell proliferation and 
metastasis. Endocrine therapy targeting E2:ERα activity often leads to development of 
antiestrogen resistance. Approximately 30% of patients who have metastatic endocrine 
therapy resistant breast cancer express ERα mutations. Two of the most common and 
therefore widely studied mutations are ERαY537S and ERαD538G. Patients whose 
metastatic breast tumors express Y537S or D538G mutations have 1 year and 6 months 
shorter median survival time than patients whose metastatic tumors express wild-type 
ERα. 
 To better characterized the aggressive phenotypes of the ERα mutations in breast 
cancer cells, we used CRISPR-Cas9 technology to replace wild-type ERα in T47D, 
human breast cancer cells, with the most common mutations, ERαY537S and ERαD538G. 
The mutant cells exhibit partially estrogen-independent and antiestrogen resistant gene 
expression and cell proliferation. A novel invasion-dissociation-rebinding (IDR) assay 
demonstrated that the mutant cells have a higher tendency to dissociate from invasion 
sites and rebind to a second site. Compared to wild type breast tumors, mutant tumors 
exhibited dramatic increases in lung metastasis. The ERαY537S mutation further 
enhanced the metastatic capability of the breast tumors. Gene set enrichment analysis 
(GSEA) showed Myc target pathways are highly induced in mutant cells. Moreover, 
chromatin immunoprecipitation showed constitutive, fulvestrant-resistant, recruitment of 
ERα mutants to the Myc enhancer region, resulting in estrogen-independent Myc 
overexpression in mutant cells and tumors. Knockdown and overexpression experiments 
showed Myc is necessary and sufficient for ligand-independent proliferation of the mutant 




Other than gain-of-function mutations, breast cancer cells can develop therapy 
resistance via recently described pathways of hormone action. Our laboratory recently 
revealed that estrogen acting through ERα, rapidly phosphorylates and activates 
phospholipase C γ (PLCγ) resulting in transient calcium release from endoplasmic 
reticulum and mild activation of the unfolded protein response. I identified that this 
anticipatory UPR is a conserved pathway shared by different mitogenic hormones 
including epidermal growth factor, estrogen and progesterone. EGF rapidly induced a 
calcium increase in the cytosol and moderate activation of the IRE1α and ATF6α arms of 
the UPR, resulting in induction of BiP chaperone.  Knockdown or inhibition of EGF 
receptor (EGFR), PLCγ or IP3 receptor (IP3R) blocks the increase in intracellular Ca2+. 
While blocking the increase in intracellular Ca2+ by locking the IP3R calcium channel with 
2-APB had no effect on EGF activation of the ERK or AKT signaling pathways, it abolished 
EGF-mediated immediate early gene expression, suggesting EGF stimulated calcium 
efflux and signaling transduction are two independent pathways and are both essential 
for EGF regulated gene expression. Knockdown of ATF6α or XBP1, which regulate UPR-
induced chaperone production, inhibited EGF stimulated cell proliferation. These data 
highlight the importance of anticipatory UPR pathway in the normal actions of mitogenic 
hormones. 
Unlike EGFR which functions as a receptor tyrosine kinase, ERα cannot directly 
phosphorylate PLCγ. Using the small molecule ERα biomodulator, BHPI, which uses the 
same pathway as E2 and induces toxic hyperactivation of the anticipatory UPR, we 
applied unbiased long-term-selection on ERα positive breast cancer cells and isolated 




We showed that 4 out of 11 T47D and almost all MCF-7 BHPI resistant clones have 
reduced Src expression.  Src overexpression by virus transduction in resistant clones 
restored sensitivity to BHPI. Furthermore, in wild-type cells, several-fold knockdown of 
Src, but not of ERα, strongly blocked BHPI-mediated UPR activation and subsequent 
HMGB1 release and necrotic cell death. Supporting Src kinase linking estrogen and 
progesterone to activation of the anticipatory UPR, we identified extranuclear complexes 
of ERα:Src:PLCγ and progesterone receptor:Src:PLCγ. Thus, Src plays a previously 
undescribed pivotal role in activation of the tumor protective anticipatory UPR, thereby 
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        Naturally occurring estrogen, such as 17β estradiol (E2), plays a central role in the 
development and maintenance of the female reproductive system. Estrogen binds to 
estrogen receptor (ER), which belongs to the steroid nuclear receptor superfamily, 
initiates downstream gene expression regulation as well as signaling transduction (1). ER 
protein consists of six functional domains: 1) the N‑terminal ligand-independent activation 
function-1 (AF‑1) domain, functions as a transcriptional activation domain; 2) the DNA 
binding domain (DBD), directly interacts with DNA; 3) the hinge domain, contains nuclear 
localization signal and interacts with heat shock proteins; 4) the ligand binding domain 
(LBD), interacts with estrogen and overlaps with the 5) ligand-dependent AF-2 domain; 
6) the c-terminal region which inhibits the receptor dimerization in the absence of estrogen 
(2). Even though original recognized as a transcription factor, estrogen receptor has been 
shown to promote various rapid, extranuclear signaling transductions that contribute to 
estrogen stimulated cell proliferation, migration and survival (3-5).  
        Although E2: ER has beneficial effects on reproductive, skeleton and cardiovascular 
system, aberrant expression of estrogen and abnormal ER function may cause initiation, 
promotion, and progression of breast cancer (6). Studies have shown the strong 
association between the risk of the breast cancer and the elevated estrogen levels in the 
blood (7, 8). At diagnosis, approximate 75% of the breast cancers express estrogen 
receptor α (ERα). Endocrine therapies for patients who have ERα positive breast cancer 
include aromatase inhibitor, which reduces estrogen production; selective estrogen 
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receptor modulators (SERM), which compete with estrogen binding with ERα; selective 
estrogen receptor degrader or down-regulator (SERD), which not only compete with 
estrogen but also degrade ERα after binding (9).  
        Although endocrine therapy is highly effective in blocking ERα activities, intrinsic and 
acquired resistance often develops. Multiple mechanisms that are responsible for 
endocrine therapy resistance have been proposed, including downregulation of ERα 
expression (10), dysregulation of cell cycle signaling molecules (11), alteration of cell 
survival pathways (12) as well as crosstalk between ERα and growth factor pathways 
(13). For patients who have metastatic breast cancer, therapies remain poor. 
 
ESTROGEN RECEPTOR α MUTATIONS 
      Even though the mechanisms underlining endocrine therapy-resistance are complex, 
several studies have provided new insights into the pathogenesis of anti-estrogen 
resistance in breast cancer. About 20 years ago, pioneer work done by Karnik and Borg 
identified nucleotide changes within ERα gene (ESR1) in hormone-independent ER-
positive breast tumors using single strand conformation polymorphism (14, 15). At the 
same time, the structure-function analysis of ERα done by Katzenellenbogen lab revealed 
that a single amino acid substitution on tyrosine 537 was able to confer estrogen-
independent constitutive transcriptional activity and association with nuclear receptor 
coactivator on breast cancer cells (16). Very recently, with the advent of sensitive DNA 
sequencing technologies, several studies unveiled that approximate 30% of the advanced 
metastatic breast cancers harbor gain-of-function ERα mutations (17-21). Notably, the 
ERα mutations identified in these metastatic endocrine therapy-resistant tumors are 
clustered within the LBD of the ERα, especially residues L536, Y537 and D538 (22).  
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    A recent biophysical and structural biology study revealed that mutant ERs bearing 
Y537S and D538G point mutations have reduced affinity to both agonist and antagonist 
(23). And the point mutations confer a stabilized agonist conformation on ERα which leads 
to antiestrogen resistance. Martin et al. demonstrated that ERαY537S had increased 
association with co-regulators GREB1 and FOXA1 than that seen for wild-type ERα using 
comparative RIME (rapid immunoprecipitation with tandem mass spectrometry of 
endogenous proteins) (24). A genome-wide study integrating RNAseq and ChIPseq data 
showed that ERα mutations lead to unique hormone-independent chromatin binding and 
distinct gene expression profiles (25). These studies provided mechanistic explanations 
for ligand-independent constitutive activities and anti-estrogen resistance seen in the ERα 
mutants. 
    While the ESR1 mutations were identified almost exclusively in the metastatic ER+ 
breast tumors (22), whether ERα mutations confer breast cancer cells with increased 
metastatic capability remains unclear. An orthotopic xenograft study done by Jeselsohn 
et al. revealed that MCF-7 tumors harboring ERαY537S mutation have much better 
metastatic capability than the tumors harboring ERαD538G mutation. Moreover, none of 
the mice bearing wild-type MCF-7 xenografts developed metastases in distant organs 
(25). This finding suggests ERα mutant cells have increased invasive and metastatic 
capability, however, the underlining mechanisms remain unknown.   
       
EPIDERMAL GROWTH FACTOR 
    Epidermal growth factor (EGF) stimulates cell proliferation and promotes tumor growth 
by binding to epidermal growth factor receptor (EGFR). The EGF receptor tyrosine kinase 
family consists of four members: EGFR (ErbB1/HER1), ErbB2 (HER2), ErbB3 (HER3) 
4 
 
and ErbB4 (HER4) (26). The ErbB family receptors are single chain transmembrane 
proteins consisting of an extracellular ligand-biding domain, a transmembrane domain 
and an intracellular tyrosine kinase domain (27). Growth factors, such as EGF, activate 
ErbBs by inducing structural changes result in formation of homodimers and heterodimers. 
ErbB2 dimerizes with all other ErbB family members, yet cannot bind any ligands by itself; 
whereas ErbB3 has an inactive pseudo-kinase intracellular domain and can only function 
in heterodimeric complex (28). Receptor dimerization leads to phosphorylation and 
activation of the intracellular kinase domain, and phosphotyrosine residues then initiate 
downstream signaling pathways including Ras/MAPK, PI3 kinase/AKT, PLCγ/PKC and 
Jak/STAT pathways (29).  
    Overexpression and constitutive activation of EGFR have been associated with cancer 
cell proliferation, survival, angiogenesis and metastasis (30). Amplification of EGFR gene 
has been described in lung cancer, gastric cancer, glioblastoma as well as breast cancer 
(31, 32). EGFR is expressed in most breast cancers and is overexpressed in ~50% of the 
triple-negative breast cancer (TNBC, ERα-, PR- and HER2-) and in highly-aggressive 
invasive breast cancer (IBC) (32-34). Other mechanisms of EGFR dysregulation include 
missense gene mutations and cross-talk with other receptor tyrosine kinases (35, 36).  
Deregulated EGFR signaling reduces cells sensitivity of anticancer drugs, therefore 
therapies combining anti-EGFR drugs with chemotherapy have been tested for triple-
negative breast tumors. Sustained erlotinib treatment increased TNBC’s sensitivity and 







    The proto-oncogene cellular Src (c-Src) is a non-receptor tyrosine kinase protein which 
plays a critical role in mediating signal transduction through interacting with multiple 
proteins and protein complexes. It is important in regulating cell adhesion, proliferation, 
migration, differentiation, survival and angiogenesis (38-41). Dysregulated Src 
expression occurs in several tumor types and has been associated with malignant 
progression of cancer (42). Overexpression of Src are found in numerous human tumors, 
including breast, pancreatic, colon, lung and prostates cancers (43-45). In breast cancer, 
Src overexpression has been correlated with latent bone metastasis (46). Using genome-
wide gene expression data from 615 breast tumors, Zhang et al. showed that expression 
of a Src response signature (SRS) in primary breast tumors is associated with latent bone 
metastasis. These data highlighted the critical role of Src in advanced tumors. 
    Src has been shown to interact with steroid hormone receptors, ERα and progesterone 
receptor (PRs), through either direct association or scaffold protein tethering (47-49). In 
breast cancers, Src is a crucial protein in a complex interaction network. Crosstalk 
between Src, EGFR and ERα contributes to tamoxifen resistance in breast cancer cells 
(50) and in patients (44). A very recent study revealed that loss of C-terminal Src kinase 
(CSK), a suppressor of Src family kinases, confers endocrine therapy resistance on ER+ 
breast cancer cells (51). Given the importance of Src in ER+ breast cancer cells, ongoing 
trials are exploring combination of Src inhibitors dasatinib and bosutinib with endocrine 
therapies (52).  
  Given its critical role in multiple signaling pathways that regulate several biological 
processes, Src expression is tightly controlled. Biochemical and structural studies have 
discerned the general mechanism by which Src activity is regulated (42). In normal cells, 
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activated Src undergoes reversible protein dephosphorylation and ubiquitin-mediated 
protein degradation (53, 54). Previous study indicates deregulation of the ubiquitin-
proteasome pathway is responsible for Src activation in cancer cells (55). The 
transcription factor CULT1 reduces proteasome mediated Src protein degradation 
leading to increased tumor cell migration (56). ErbB2 increases Src protein stability 
through inhibiting calpain protease and promotes breast cancer metastasis (57). Efforts 
have been made to trigger Src protein instability and prevent maturation, therefore 
diminish Src activity. Src degradation was achieved using drugs that inhibit HSP90 activity 
or disrupt the association of HSP90 with c-Src (58, 59).   
     
UNFOLDED PROTEIN RESPONSE  
    Endoplasmic reticulum (EnR) is the major organelle in the cell where the secreted and 
membrane proteins get folded and modified. The protein quality control and homeostasis 
within the EnR is monitored by a collection of conserved signaling pathways termed the 
unfolded protein response (UPR). Three arms of the UPR have been identified in the EnR, 
namely the inositol-requiring protein-1 (IRE1), activating transcription factor-6 (ATF6) and 
protein kinase RNA (PKR)-like ER kinase (PERK) (60, 61). Mild UPR activation increases 
lipid synthesis to expand EnR membrane and induces molecular chaperone production 
to boost the protein folding capacity in the cells (61). In the cancer cells, which are 
exposed to intrinsic and external insults that may trigger the EnR stress, the UPR is 
usually upregulated in comparison to cells in normal tissues (62). Recently, our laboratory 
and others discovered that mitogenic steroid and peptide hormones activate the 
anticipatory UPR and prepare cells for the future needs of increased protein folding 
capacity that may company cell proliferation (63, 64). Estrogen activates a rapid calcium 
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release from the EnR mediated by phosphorylated phospholipase C gamma (PLCγ). This 
mild calcium depletion within the EnR lumen result in activation of the protective 
anticipatory UPR and increased expression of molecular chaperones (63).  
    Under severe and irreversible EnR stresses, sustained reactive UPR activation induces 
pro-death pathways. There are multiple apoptosis mechanisms by which EnR could 
trigger and eventually elicit cell death, involving: (1) induction of the proapoptotic 
transcription factor CHOP and GADD34 by hyperactivating PERK-eIF2α (65), (2) 
tethering IRE1α to ASK-JNK cascade (66), (3) induction of calcium release from EnR 
lumen leading to mitochondria fission and cytochrome c release (67). How sustained 
anticipatory UPR activation kills cancer cells was recently revealed by our laboratory (68, 
69). A small molecule anticancer drug, BHPI, acting through ERα, distorts anticipatory 
UPR resulting in persistent activation of PLCγ and sustained production of IP3, allowing 
continued calcium efflux from EnR lumen into the cytosol. To restore calcium homeostasis, 
cells activate ATP dependent sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 
pumps. Because the IP3R Ca2+ channel stays open, Ca2+ pumped back into the EnR 
by SERCA leaks back out. This futile cycle rapidly depletes ATP and eventually leads to 
necrotic cell death (69).  
 
OVERVIEW OF THESIS  
    Here, using breast cancer cell lines bearing the ERαY537S and ERαD538G mutations 
(70), I characterized the aggressive phenotypes of the mutant cells. I used RNA 
sequencing analysis to demonstrate the unique gene expression patterns of the ERα 
mutants; showed that ERα mutation bearing cells have increased invasion ability using 
the newly developed invasion-dissociation-rebinding assay; validated that the mutations 
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confer breast cancer cells with increased metastatic capability. I also showed that 
hormone-independent constitutive overexpression of Myc pathway is responsible for anti-
estrogen resistant cell proliferation observed in the mutant cells but had no effect in 
promoting invasiveness of the breast cancer cells. 
    Furthermore, I demonstrated that other mitogenic hormones including EGF and 
progesterone can activate the anticipatory UPR in breast cancer cells. EGF induced 
calcium release from the EnR lumen into the cytosol is required for EGF regulated 
immediate early gene expression and mild activation of the UPR increased molecular 
chaperones prepare cells for future cell proliferation. Using an unbiased long-term BHPI 
selection, we identified MCF-7 and T47D clones that can grow in the presence of lethal 
concentration BHPI. 4 out of 11 T47D and almost all MCF-7 BHPI-resistant clones have 
reduced expression of proto-oncogene c-Src. Knockdown Src in breast cancer cells 
rescued cells from BHPI induced necrotic cell death and restore Src expression in BHPI-
resistant clones re-sensitized the cells to UPR hyperactivation. Src is not only the protein 
kinase couples activation of estrogen receptor to the anticipatory UPR activation but also 













1. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson Gr, et al. 
Mechanisms of estrogen action. Physiol Rev. 2001;81(4):1535-65. 
2. Kumar V, Green S, Stack G, Berry M, Jin J-R, Chambon P. Functional domains of the 
human estrogen receptor. Cell. 1987;51(6):941-51. 
3. Filardo EJ, Quinn JA, Bland KI, Frackelton Jr AR. Estrogen-induced activation of Erk-
1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via 
trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol 
Endocrinol. 2000;14(10):1649-60. 
4. Kelly MJ, Levin ER. Rapid actions of plasma membrane estrogen receptors. Trends in 
Endocrinology & Metabolism. 2001;12(4):152-6. 
5. Sun M, Paciga JE, Feldman RI, Yuan Z-q, Coppola D, Lu YY, et al. 
Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and 
is induced by estrogen receptor α (ERα) via interaction between ERα and PI3K. Cancer 
Res. 2001;61(16):5985-91. 
6. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. New Engl J Med. 
2006;354(3):270-82. 
7. Wolff MS, Toniolo PG, Lee EW, Rivera M, Dubin N. Blood levels of organochlorine 
residues and risk of breast cancer. JNCI: Journal of the National Cancer Institute. 
1993;85(8):648-52. 
8. Wu AH, Pike MC, Stram DO. Meta-analysis: dietary fat intake, serum estrogen levels, 
and the risk of breast cancer. J Natl Cancer Inst. 1999;91(6):529-34. 
10 
 
9. Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer - An overview 
and update. Mol Cell Endocrinol. 2015. 
10. Encarnación CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. 
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. 
Breast cancer research and treatment. 1993;26(3):237-46. 
11. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CF. Cyclin-E is a strong 
predictor of endocrine therapy failure in human breast cancer. Oncogene. 
2003;22(31):4898. 
12. Riggins RB, Bouton AH, Liu MC, Clarke R. Antiestrogens, aromatase inhibitors, and 
apoptosis in breast cancer. Vitamins & Hormones. 2005;71:201-37. 
13. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor 
and growth factor receptor pathways as a cause for endocrine therapy resistance in 
breast cancer. Clin Cancer Res. 2005;11(2):865s-70s. 
14. Karnik PS, Kulkarni S, Liu X-P, Budd GT, Bukowski RM. Estrogen receptor mutations 
in tamoxifen-resistant breast cancer. Cancer Res. 1994;54(2):349-53. 
15. Zhang Q-X, Borg Å, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant 
with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 
1997;57(7):1244-9. 
16. Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS. Constitutively 
active human estrogen receptors containing amino acid substitutions for tyrosine 537 in 
the receptor protein. Mol Endocrinol. 1996;10(11):1388-98. 
17. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-
Angulo AM, et al. Emergence of constitutively active estrogen receptor-α mutations in 
11 
 
pretreated advanced estrogen receptor–positive breast cancer. Clin Cancer Res. 
2014;20(7):1757-67. 
18. Robinson DR, Wu Y-M, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 
mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-
51. 
19. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain 
mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439-45. 
20. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, 
Jeselsohn R, et al. D538G mutation in estrogen receptor-α: a novel mechanism for 
acquired endocrine resistance in breast cancer. Cancer Res. 2013;73(23):6856-64. 
21. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant 
ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. 
Cell reports. 2013;4(6):1116-30. 
22. Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations—a 
mechanism for acquired endocrine resistance in breast cancer. Nature reviews Clinical 
oncology. 2015;12(10):573. 
23. Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, et al. 
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer 
endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. 
2016;5:e12792. 
24. Martin L-A, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, et al. Discovery 
of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine 
resistance. Nat Commun. 2017;8:1865. 
12 
 
25. Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, et al. Allele-specific 
chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. 
Cancer Cell. 2018;33(2):173-86. e5. 
26. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal 
growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16. 
27. Wieduwilt M, Moasser M. The epidermal growth factor receptor family: biology driving 
targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566-84. 
28. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor 
heterodimerization in development and cancer. The EMBO journal. 2000;19(13):3159-67. 
29. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for 
targeted therapy. Clin Cancer Res. 2006;12(18):5268-72. 
30. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello M, Luca A, et al. The ErbB 
receptors and their ligands in cancer: an overview. Curr Drug Targets. 2005;6(3):243-57. 
31. Herbst RS, Langer CJ, editors. Epidermal growth factor receptors as a target for 
cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and 
neck cancers. Semin Oncol; 2002: Elsevier. 
32. Reis‐Filho JS, Pinheiro C, Lambros M, Milanezi F, Carvalho S, Savage K, et al. EGFR 
amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 
2006;209(4):445-53. 
33. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-




34. Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H. Prognostic impact of 
human epidermal growth factor-like receptor 2 and hormone receptor status in 
inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California 
Cancer Registry. Breast Cancer Res. 2009;11(1):R9. 
35. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of 
epidermal growth factor receptor in breast cancer. Breast cancer research and treatment. 
2012;136(2):331-45. 
36. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk 
between estrogen receptor and growth factor pathways as a molecular target for 
overcoming endocrine resistance. Clin Cancer Res. 2004;10(1):331s-6s. 
37. van Anken E, Romijn EP, Maggioni C, Mezghrani A, Sitia R, Braakman I, et al. 
Sequential waves of functionally related proteins are expressed when B cells prepare for 
antibody secretion. Immunity. 2003;18(2):243-53. 
38. Castoria G, Giovannelli P, Lombardi M, De Rosa C, Giraldi T, De Falco A, et al. 
Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent 
nuclear export and cell cycle progression in breast cancer cells. Oncogene. 
2012;31(46):4868-77. 
39. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, et al. 
Steroid‐induced androgen receptor–oestradiol receptor β–Src complex triggers prostate 
cancer cell proliferation. The EMBO journal. 2000;19(20):5406-17. 
40. Khare S, Bolt M, Wali R, Skarosi S, Roy H, Niedziela S, et al. 1, 25 dihydroxyvitamin 
D3 stimulates phospholipase C-gamma in rat colonocytes: role of c-Src in PLC-gamma 
activation. J Clin Invest. 1997;99(8):1831. 
14 
 
41. Dhar A, Shukla S. Electrotransjection of pp60v-src monoclonal antibody inhibits 
activation of phospholipase C in platelets. A new mechanism for platelet-activating factor 
responses. J Biol Chem. 1994;269(12):9123-7. 
42. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. 
Clin Cancer Res. 2006;12(5):1398-401. 
43. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. 
Oncogene. 2000;19(49):5636. 
44. Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise 
into triumph. Trends Pharmacol Sci. 2012;33(3):122-8. 
45. Giaccone G, Zucali P. Src as a potential therapeutic target in non-small-cell lung 
cancer. Ann Oncol. 2008;19(7):1219-23. 
46. Zhang XH-F, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, et al. Latent bone 
metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 
2009;16(1):67-78. 
47. Sun J, Zhou W, Kaliappan K, Nawaz Z, Slingerland JM. ERα phosphorylation at Y537 
by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target 
gene expression. Mol Endocrinol. 2012;26(9):1567-77. 
48. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, et 
al. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 
domains and activates c-Src family tyrosine kinases. Mol Cell. 2001;8(2):269-80. 
49. Song RX, Zhang Z, Santen RJ. Estrogen rapid action via protein complex formation 
involving ERα and Src. Trends in Endocrinology & Metabolism. 2005;16(8):347-53. 
15 
 
50. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen 
resistance. Cancer Lett. 2007;256(1):1-24. 
51. Xiao T, Li W, Wang X, Xu H, Yang J, Wu Q, et al. Estrogen-regulated feedback loop 
limits the efficacy of estrogen receptor–targeted breast cancer therapy. Proc Natl Acad 
Sci. 2018;115(31):7869-78. 
52. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and 
other solid malignancies. Clin Cancer Res. 2010;16(14):3526-32. 
53. Harris KF, Shoji I, Cooper EM, Kumar S, Oda H, Howley PM. Ubiquitin-mediated 
degradation of active Src tyrosine kinase. Proc Natl Acad Sci. 1999;96(24):13738-43. 
54. Roskoski Jr R. Src kinase regulation by phosphorylation and dephosphorylation. 
Biochem Biophys Res Commun. 2005;331(1):1-14. 
55. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. 
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2002;1602(2):114-30. 
56. Aleksic T, Bechtel M, Krndija D, von Wichert G, Knobel B, Giehl K, et al. CUTL1 
promotes tumor cell migration by decreasing proteasome-mediated Src degradation. 
Oncogene. 2007;26(40):5939. 
57. Tan M, Li P, Klos KS, Lu J, Lan K-H, Nagata Y, et al. ErbB2 promotes Src synthesis 
and stability: novel mechanisms of Src activation that confer breast cancer metastasis. 
Cancer Res. 2005;65(5):1858-67. 
58. Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI, et al. 
Quantitative analysis of HSP90-client interactions reveals principles of substrate 
recognition. Cell. 2012;150(5):987-1001. 
16 
 
59. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist 
geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before 
their degradation by the proteasome. Cell Growth and Differentiation-Publication 
American Association for Cancer Research. 2000;11(7):355-60. 
60. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic 
regulation. Science. 2011;334(6059):1081-6. 
61. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein 
response. Nature reviews Molecular cell biology. 2007;8(7):519-29. 
62. Tsai YC, Weissman AM. The unfolded protein response, degradation from the 
endoplasmic reticulum, and cancer. Genes & cancer. 2010;1(7):764-78. 
63. Andruska N, Zheng X, Yang X, Helferich WG, Shapiro DJ. Anticipatory estrogen 
activation of the unfolded protein response is linked to cell proliferation and poor survival 
in estrogen receptor alpha-positive breast cancer. Oncogene. 2015;34(29):3760-9. 
64. Karali E, Bellou S, Stellas D, Klinakis A, Murphy C, Fotsis T. VEGF Signals through 
ATF6 and PERK to Promote Endothelial Cell Survival and Angiogenesis in the Absence 
of ER Stress. Mol Cell. 2014;54(4):559-72. 
65. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a 
vicious cycle or a double-edged sword? Antioxidants & redox signaling. 2007;9(12):2277-
94. 
66. Verfaillie T, Garg AD, Agostinis P. Targeting ER stress induced apoptosis and 
inflammation in cancer. Cancer Lett. 2013;332(2):249-64. 
67. Breckenridge DG, Stojanovic M, Marcellus RC, Shore GC. Caspase cleavage product 
of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, 
17 
 
enhancing cytochrome c release to the cytosol. The Journal of cell biology. 
2003;160(7):1115-27. 
68. Andruska ND, Zheng X, Yang X, Mao C, Cherian MM, Mahapatra L, et al. Estrogen 
receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and 
induces tumor regression. Proc Natl Acad Sci. 2015;112(15):4737-42. 
69. Livezey M, Huang R, Hergenrother PJ, Shapiro DJ. Strong and sustained activation 
of the anticipatory unfolded protein response induces necrotic cell death. Cell Death & 
Differentiation. 2018;25(10):1796. 
70. Mao C, Livezey M, Kim JE, Shapiro DJ. Antiestrogen Resistant Cell Lines Expressing 
Estrogen Receptor alpha Mutations Upregulate the Unfolded Protein Response and are 



















ESTROGEN-INDEPENDENT MYC OVEREXPRESSION CONFERS ENDOCRINE 
THERAPY RESISTANCE ON BREAST CANCER CELLS EXPRESSING ERαY537S 
AND ERαD538G MUTATIONS 1 
 
ABSTRACT 
Approximately 30% of metastatic breast cancers harbor estrogen receptor α (ERα) 
mutations associated with resistance to endocrine therapy and reduced survival. 
Consistent with their constitutive proliferation, T47D and MCF7 cells in which wild-type 
ERα is replaced by the most common mutations, ERαY537S and ERαD538G, exhibit 
partially estrogen-independent gene expression. A novel invasion/dissociation/rebinding 
assay demonstrated that the mutant cells have a higher tendency to dissociate from 
invasion sites and rebind to a second site. Compared to ERαD538G breast tumors, 
ERαY537S tumors exhibited a dramatic increase in lung metastasis. Transcriptome 
analysis showed that the ERαY537S and ERαD538G mutations each elicit a unique gene 
expression profile. Gene set enrichment analysis showed Myc target pathways are highly 
induced in mutant cells. Moreover, chromatin immunoprecipitation showed constitutive, 
fulvestrant-resistant, recruitment of ERα mutants to the Myc enhancer region, resulting in 
estrogen-independent Myc overexpression in mutant cells and tumors. Knockdown and 
virus transduction showed Myc is necessary and sufficient for ligand-independent 
proliferation of the mutant cells but had no effect on metastasis-related phenotypes. Thus,  
 
1 This chapter appeared in its entirety in Cancer Letters. Yu, L. et al. (2019) Estrogen-independent Myc overexpression confers 
endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations. Cancer letters, 442, 373-382. 
Data in Figures 2.5 (F) and 2.6 (D, E) was obtained by Mr. Lawrence Wang and Mr. Darjan Duraki. Data in Figure 2.6 (B, C) was 
obtained by Dr. Chengjian Mao and data in Figure 2.11 (B) was obtained by Mr. Lawrence Wang. 
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Myc plays a key role in aggressive proliferation-related phenotypes exhibited by breast 




At diagnosis, approximately 75% of breast cancers are estrogen receptor alpha (ERα) 
positive (1). Endocrine therapies for ERα positive tumors include aromatase inhibitors, 
tamoxifen, fulvestrant (ICI-182,780/Faslodex) and other selective estrogen receptor 
modulators, and degraders (2-4). Although endocrine therapies are effective initially, 
resistance often develops (5). While resistance mechanisms are diverse, approximately 
30% of metastatic tumors harbor ERα ligand binding domain (LBD) mutations, most 
commonly ERαD538G and ERαY537S (6-8). These mutations are rare in primary tumors 
and increase after endocrine therapy (9, 10).  
 To characterize these aggressive tumors, we, and others used CRISPR/Cas9, long-
term-estrogen-deprived selection and other methods to generate cell lines bearing ERα 
mutations (11-16). Consistent with their estrogen-independent proliferation and tamoxifen 
resistance (11), structural and modeling studies suggest ERαY537S and ERαD538G 
mutants are locked in active conformations and exhibit reduced affinity for 4-
hydroxytamoxifen (OHT) (17). Moreover, ESR1 mutations increase breast cancer stem 
cell activity (16). Since invasiveness of these cell lines, was largely unstudied, we used a 
novel, invasion-dissociation-rebinding (IDR) assay to analyze metastasis-related 
properties. Compared to parental cells, T47D-ERαY537S (TYS) and T47D-ERαD538G 
(TDG) cells (11) exhibit increased invasiveness and TYS and TDG cells and MCF7-
derived MCF7-Y537S and MCF7-D538G cells all exhibit increased dissociation and 
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rebinding at a second site. Patients whose breast cancers express the ERαY537S and 
ERαD538G mutations have 1-year and 6-month shorter lifespans, respectively, than 
patients whose tumors express wild type ERα (18). Notably, compared to the ERαD538G 
(TDG) tumors, the more lethal ERαY537S (TYS) tumors exhibited greatly increased lung 
metastases; wild type ERα (T47D) tumors did not metastasize. Thus, the aggressive 
phenotypes of cells expressing ERαY537S and ERαD538G include resistance to drugs 
targeting estrogen production and binding to ERα, estrogen-independent proliferation and 
an increase in stemness and metastasis-related properties. 
 How these aggressive phenotypes link to the mutant cells transcriptome was largely 
unknown. A few studies began transcriptome characterization (12, 14, 19), and recent 
studies identified specific coactivators and unique binding sites of mutant ERα (15, 20). 
Remaining to be done were detailed transcriptome comparisons of ERαD538G and 
ERαY537S mutant cells, analysis of invasiveness, and identification and analysis of 
specific genes contributing to the aggressive phenotypes of mutation-bearing tumors. 
To identify pathways that might play a role in these aggressive phenotypes, we 
performed unbiased RNAseq analysis of global gene expression profiles. Compared to 
parental T47D cells, TYS and TDG cells exhibit distinct patterns of gene expression. 
Gene set enrichment analysis (GSEA) of T47D and MCF7 RNAseq data showed Myc 
targets are highly induced in mutant cells. Myc is important in diverse cellular processes 
including proliferation, biosynthesis and global metabolism(21, 22). Dysregulated Myc 
expression contributes to malignant transformation, tumor progression and reduced 
responsiveness to anticancer drugs(23-28). In breast cancer, Myc overexpression is 
associated with tamoxifen resistance in vitro and in patients(5). 
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Chromatin immunoprecipitation (ChIP) demonstrated estrogen-independent, 
fulvestrant-resistant, recruitment of ERαY537S and ERαD538G to the Myc enhancer. 
Moreover, cell and tumor studies demonstrated estrogen-independent Myc expression in 
the mutants is higher than in estrogen-treated controls. Myc knockdown blocked 
estrogen-independent growth of TYS and TDG cells. Notably, expression of Myc in 
estrogen-deprived T47D cells partially reproduces the estrogen-independent proliferation 
and antiestrogen resistance, but not the increased invasiveness, dissociation and 
rebinding, displayed by mutant cells. Our identification of a role for Myc in a sub-set of the 
aggressive phenotypes displayed by ERα mutant cells illustrates the utility of these cell 
models and transcriptome data as tools for identifying pathways that contribute to the 
aggressiveness of ESR1 mutant cells. 
 
MATERIALS AND METHODS 
Cell culture and proliferation assays 
Media and conditions were previously described (29). T47D, MCF7 and the mutant 
clones were generated and cultured as described(11, 14). Cells were authenticated at 
University of Arizona Genetics Core. E2, fulvestrant and z-OHT were from Sigma. JQ1 
was from Selleck. Cells proliferation assays were as described (29).  
Generation of luciferase-expressing cell lines 
The pcDNA3-Luc vector was transfected into T47D, TYS clone 4 and TDG clone 1 cells, 
respectively. Colonies were selected for 2 weeks in G418. 
qRT-PCR and RNAseq data analysis 
Cells were cultured and plated as described (29). For RNAseq, T47D, TYS and TDG 
cells were treated with vehicle (EtOH) or 10 nM E2. Total RNA of three biological 
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replicates was collected and cDNA library were prepared using TruSeq Stranded 
mRNAseq Sample Prep kit (Illumina). Single-end RNA sequencing was performed by 
the University of Illinois High-Throughput Sequencing Unit (HiSeq 4000 (Illumina)). 
Software used for data analysis is in Table 1. Raw and processed data of RNAseq were 
deposited in NCBI GEO [GSE108304]. 
Western blot 
Whole cell extracts were prepared and western blots were performed as described (29). 
Antibodies are in Table 2. 
siRNA knockdowns 
siRNA knockdowns were performed using DharmaFECT1 and 100 nM ON-TARGET 
plus non-targeting pool or SMARTpools for ERα and c-Myc (Dharmacon). Transfection 
conditions were as described (29).  
2.6 Chromatin immunoprecipitation (ChIP) 
Chromatin was prepared from three biological replicates incubated 30 min in 10 nM E2 
or pretreated with 500 nM fulvestrant for 10 min before E2 addition. Samples were 
sheared using an M220 Focused-ultra sonicator (Covaris). ChIP assays were as 
described (30). 
Lentivirus infection 
Lentivirus was produced by cotransfecting pCDH-puro-cMyc (Addgene #46970) or 
pHIV-Luciferase vector (Addgene #21375) with packaging vectors pCI-VSVG (Addgene 
#1733) and psPAX2 (Addgene #12260) into HEK293 cells using Lipofectamine 3000 




Cell invasion assay 
Millipore polycarbonate cell culture inserts (12 μm) were coated with 25 μg/ml collagen 
or Matrigel (Corning). 100,000 luciferase-expressing cells in 0.5 ml medium containing 
0.1% BSA were placed in the upper chamber and 0.55 ml medium containing 20% CD-
FBS were in bottom chamber (31, 32). After 24h, upper chamber cells were removed. 
150 μl Bright-GloTM (Promega) was added into the wells and luciferase activity was 
measured using a PHERAStar plate-reader (BMG Labtech). 
Mouse xenograft  
All animal studies were approved by the University of Illinois Institutional Animal Care 
(IACUC) committee. Five female mice were used for each cell line. Estrogen pellets (90 
day; Innovative Research of America) were implanted subcutaneously 30 days prior to 
T47D-Luc cell injection; a second estrogen-release pellet was implanted 3 months after 
the first pellet. No estrogen supplementation was used in the TYS-Luc and TDG-Luc 
mice. 5 × 106 T47D, TYS and TDG cells in Matrigel stably expressing the luciferase 
gene (T47D-Luc, TYS-Luc and TDG-Luc) were grafted orthotopically into 
ovariectomized NSG mice. Mice were anesthetized, injected with luciferin substrate and 
tumor bioluminescence was monitored using an IVIS Spectrum CT live-animal imaging 
system (PerkinElmer). Based on the growth of the primary breast tumors, mice were 
sacrificed about 2 months (TYS-Luc), about 3 months (T47D-Luc) and about 4 months 
(TDG-Luc), after initiating tumor growth. Consistent with in vitro results for the cell lines, 
the TDG-Luc tumors have about 12-fold higher luciferase emission per mg excised 
breast tumor weight than the TYS-Luc tumors. Therefore, the TYS-Luc and TDG-Luc 
lung metastases data in Fig. 2E was normalized for the difference in luciferase 
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emission. Since no lung metastases were observed for T47D-Luc, normalization was 
not relevant. 
Statistics 
Each in vitro experiment was performed at least three times. Statistical significance was 
determined by an unpaired two-tailed Student’s t-test or ANOVA using SPSS statistics 




T47D-ERαY537S (TYS) and T47D-ERαD538G (TDG) cells display a constitutive 
gene expression pattern 
To evaluate the effect of ERα mutations on gene expression, we performed RNAseq in 
T47D, TYS and TDG breast cancer cells. Without estrogen, T47D, TYS and TDG cells 
exhibit very different gene expression patterns. Expression of 3669 and 2592 genes were 
altered in TYS and TDG cells, respectively (Table 3); 2020 of these genes were shared 
by TYS and TDG cells (Fig. 1A). To evaluate expression of direct and indirect ERα target 
genes, we chose 4- and 24-hour E2 treatment. After 4h E2 treatment, 317 genes were 
differentially regulated in T47D cells; 272 of these genes are shared by one or both mutant 
cells (Fig. 2A). A heatmap of over 13,000 genes and a multi-dimensional scaling (MDS) 
plot show a modest effect of 4h E2 treatment on the T47D transcriptome, with minimal 
effects on the mutants (Fig. 1B, Fig. 2D).  
24h E2 incubation dramatically increased differentially expressed T47D cell genes; 
most of these genes (1509/1748) were differentially expressed in one or both mutant cells 
(Fig. 2B). Compared to vehicle, the heatmap and MDS plot display a large shift of the E2-
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treated T47D transcriptome toward the TDG cells (Fig. 2C, E). To further compare T47D, 
TYS and TDG cells, we used qPCR to analyze expression of well-characterized ERα 
target genes. For all genes tested, estrogen responses were robust in T47D, reduced in 
TDG and minimal in TYS cells (Fig. 2F). 
 To test for off-target effects of CRISPR/Cas9, we evaluated expression of these genes 
both in additional clones of T47D-ERαY537S (clone 39) and T47D-ERαD538G (clone 28) 
and in MCF7 cell lines containing ERαY537S and ERαD538G mutations generated 
through virus infection, not CRISPR. Consistently, ERαY537S cells responded less to 
estrogen than ERαD538G and parental cells (Fig. 3, 4A). Overall, the data demonstrate 
estrogen-independent gene expression in the mutant cells.  
 
ERαY537S and ERαD538G cells have distinct gene expression profiles and exhibit 
aggressive phenotypes 
  Although TYS and TDG cells both display ligand-independent gene expression, their 
gene expression profiles differ. MDS shows that after 24h E2 treatment T47D cells shifted 
towards TDG cells, indicating that E2-stimulated T47D and TDG cells have more closely 
related gene expression patterns. Notably, E2 treatment had almost no effect on TYS 
gene expression (Fig. 2E). To further address potential off-target effects of CRISPR/Cas9 
(33), we generated an MDS plot from raw RNAseq datasets of MCF7, and virus-
generated MCF7-Y537S and MCF7-D538G [SRA: SRP093386] (14) (Fig. 4C). 
Consistent with the T47D data, the estrogen-treated MCF7 gene expression profile is 
closer to the MCF7-D538G cell profile and MCF7-Y537S cells respond least to estrogen. 
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  To begin to explore the interplay between gene expression patterns and the aggressive 
phenotypes induced by ERα mutations, we examined proliferation and resistance to 
endocrine therapies. Parental T47D cells did not grow in estrogen-depleted medium, 
while TYS and TDG cells (Fig. 5A), other mutant T47D clones and MCF7-Y537S and 
MCF7-D538G cells all exhibited robust estrogen-independent proliferation (Fig. 5B, C). 
We used dose-response studies to evaluate resistance to endocrine therapies. In T47D 
cells, proliferation was nearly abolished by a 25- to 100-fold molar excess over estrogen 
of z-4-hydroxytamoxifen (OHT), or fulvestrant/ICI. In contrast, TYS and TDG cells 
exhibited partial resistance to OHT and fulvestrant (Fig. 5A). Notably, in MCF7 cells, a 
50-fold molar excess of OHT or fulvestrant abolished estrogen induced cell proliferation, 
but had no effect on proliferation of MCF7-Y537S and MCF7-D538G cells (Fig. 5C). Thus, 
both T47D- and MCF7-derived cell lines containing ERαY537S and ERαD538G exhibit 
estrogen-independent proliferation and resistance to OHT and fulvestrant. 
  Although ESR1 mutations are observed in metastatic breast cancers, metastasis is 
difficult to model in cell culture. To probe steps in metastasis beyond invasion, we 
developed a quantitative invasion-dissociation-rebinding (IDR) assay (Fig. 6A). Using 
T47D, TYS and TDG cell lines stably expressing luciferase, we quantified both total cells 
that invaded through collagen- or Matrigel-coated membranes (Fig. 6B; Invaded Cells) 
and cells that invaded and then dissociated from their membrane invasion site and 
rebound to a second site (Fig. 6B; IDR cells). ERα mutations significantly increased 
invasiveness. Even though more TDG cells invaded through membranes, more TYS cells 
dissociated and rebound (Fig. 5D, Fig. 6B, C). Using lentiviral transduction of luciferase, 
we performed IDR assays on MCF7, MCF7-Y537S and MCF7-D538G cells. Compared 
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to MCF7 cells, ERα mutations did not increase invasion, but strongly elevated dissociation 
and rebinding (Fig. 5E). Increased ability to dissociate and rebind at a second site is a 
previously unexplored metastasis-related property of ERα mutant cells. 
  We evaluated the ability of orthotopic breast tumors derived from TYS-Luc (ERαY537S) 
and TDG-Luc (ERαD538G) cells to metastasize to lung and investigated whether invasion 
or dissociation-rebinding correlated with in vivo metastatic potential. As a control, we used 
estrogen-supplemented T47D-Luc, which expresses wild type ERα. All the mice grew 
primary tumors (Fig. 5F). Because the light output from the large primary breast tumors 
masks signals from lung metastases, we evaluated the extent of lung metastasis using 
ex vivo bioluminescent imaging (BLI) of lungs excised from tumor bearing mice. 
Consistent with earlier reports (34, 35), lung metastases were not detected in mice 
harboring T47D-Luc xenografts (Fig. 6D).  All mice harboring primary breast tumors 
expressing ERαY537S and ERαD538G developed lung metastases (Fig. 6D). Since light 
emission per mg of TDG-Luc breast tumor is 12-fold higher than from TYS-Luc breast 
tumors, the moderately lower visualized level of metastasis seen in the lungs of TDG-Luc 
tumors compared to TYS-Luc tumors (Fig. 6D) reflects a dramatically lower level of lung 
metastasis. Normalized for this difference in light emission, lung metastases from mice 
with primary TYS-Luc breast tumors averaged 32 times higher signals than lung 
metastases from mice harboring primary TDG breast tumors (Fig. 6E). A >20-fold 
increase in metastases in mice harboring TYS-Luc breast tumors compared to TDG-Luc 
tumors is also observed if the metastases data is calculated as the ratio of light emission 





ERαY537S and ERαD538G mutations elicit constitutive hormone-independent 
pathway alterations 
To probe pathways related to therapy resistance and metastatic potential in ERαY537S 
and ERαD538G cells, we used the RNAseq datasets to perform GSEA. Highly 
upregulated pathways were largely consistent across T47D and MCF7 mutant cells, with 
little estrogen dependence (Fig. 7, 8). Consistent with estrogen-independence, without 
estrogen, estrogen response pathways were upregulated in mutant cells (Fig. 7A). Cell 
cycle related pathways were constitutively elevated in mutant cells. Confirming our earlier 
observation (11), the tumor protective unfolded protein response (UPR) was upregulated 
in T47D and MCF7 mutant cells.  
Consistent with direct regulation by ER, in T47D cells after 4h estrogen treatment, 
“Estrogen_Response” pathways were the top upregulated pathways, (Fig. 7B). After 24h 
estrogen treatment, most pathways highly upregulated in mutant cells were also 
upregulated in parental T47D cells. 
 
The Myc pathway exhibits constitutive and elevated activation in mutant cells 
At 24 hours, Myc targets were the top upregulated pathway in mutant cells (Fig. 7, 8). 
There is a strong correlation between Myc targets and cancer stemness, which can lead 
to therapy resistance and metastasis(36). Compared to T47D cells, Myc target genes 
important in DNA replication, protein synthesis and cell cycle progression are 
constitutively overexpressed in TYS and TDG cells (Fig. 9A, B).  
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As expected, ERα knockdown blocked estrogen-stimulated proliferation of T47D cells 
and proliferation of TYS and TDG cells with and without E2 (Fig. 10A). Consistent with a 
role for Myc, ERα knockdown also blocked estrogen stimulated Myc expression in T47D 
cells and reduced Myc expression in mutant cells (Fig. 10B). 
We next assessed whether Myc expression in the TYS and TDG cells was constitutive 
and resistant to antagonists. Chromatin immunoprecipitation (ChIP) in T47D cells showed 
that E2 stimulates, and a 50X excess of ICI/fulvestrant blocks, recruitment of ERα to the 
Myc enhancer region. Recruitment of ERαY537S was constitutive with little effect of E2; 
binding of ERαD538G was partially constitutive and was further increased by E2. ICI 
reduced, but did not eliminate binding of ERα mutants to Myc enhancer (Fig. 9C).  
Moreover, compared to T47D cells, Myc mRNA expression in TYS and TDG cells was 
constitutive and elevated (Fig. 9D). Notably, compared to estrogen-treated T47D tumors, 
vehicle-treated TYS and TDG tumors exhibited higher Myc mRNA expression (Fig. 9E). 
Consistent with the ChIP, OHT or ICI abolished E2-induction of Myc mRNA in T47D cells, 
but reduced Myc levels less than 50% in TYS and TDG cells (Fig. 9D). Western blot 
analysis confirmed that, in T47D cells, Myc protein exhibits fulvestrant-sensitive is E2-
induction. In contrast, in TYS and TDG cells, Myc levels are high in vehicle-treated cells, 
show little increase in response to E2 and are only modestly sensitive to OHT and 
fulvestrant (Fig. 9F, G). Constitutive Myc expression and antiestrogen resistance were 
also observed in other T47D mutant clones and in MCF7 mutant cells (Fig. 10C, D) 
In T47D cells, but not in the mutant cells, antiestrogens downregulated induction of 
mRNA and protein encoding Myc cell cycle effector targets, Cyclin E and E2F-2 (Fig. 9F, 
G, Fig. 10E, F). Although OHT and fulvestrant blocked E2 induction of E2F-2 mRNA in 
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mutant cells, it was still expressed at levels >5 fold higher than in T47D cells (Fig. 10E). 
These data help explain why TYS and TDG cells continue to proliferate during endocrine 
therapy. 
 
Myc expression is required for estrogen-independent proliferation of TYS and TDG 
cells and is sufficient to confer partial resistance to endocrine therapy 
  To further evaluate Myc’s role, we altered its level. After RNAi knockdown, levels of Myc 
protein in mutant cells and vehicle treated T47D cells were similar (Fig. 11A). Myc 
knockdown greatly reduced E2 stimulated proliferation of T47D cells and abolished 
estrogen-independent proliferation of mutant cells (Fig. 11B). Targeting Myc expression 
through the bromodomain inhibitor JQ1 is an emerging therapeutic strategy(37, 38). JQ1 
reduced Myc expression by ~50% (Fig. 11C) and abolished proliferation of T47D, TYS 
and TDG cells (Fig. 11D). As a bromodomain inhibitor, JQ1 acts on diverse targets. These 
data suggest other pathways promote proliferation in TYS and TDG cells by working 
synergistically with Myc. 
Since reducing constitutive Myc expression abolished estrogen-independent 
proliferation of TYS and TDG cells, we explored whether constitutive Myc expression in 
estrogen-deprived T47D cells could recapitulate their aggressive phenotypes. T47D cells 
were infected with lentivirus expressing Myc, or a luciferase control. After infection, Myc 
protein levels in T47D cells were increased to levels similar to those in TYS and TDG 
cells (Fig. 11C, E). Myc overexpression in OHT- and fulvestrant-treated T47D cells did 
not alter ERα levels, but increased levels of the downstream effector, Cyclin E (Fig. 11E). 
Constitutive Myc expression facilitated both E2-independent and E2-dependent 
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proliferation of T47D cells (Fig. 11F). Notably, compared to control cells, Myc 
overexpression increased resistance to OHT and fulvestrant (Fig. 11F). However, Myc 
overexpression had no effect on the number of invaded cells, or on the number of 
dissociated and rebound cells (Fig. 11G, H). Thus, while estrogen-independent 
expression of Myc in T47D cells does not reproduce the metastasis-related phenotypes 
exhibited by ERα mutant cells, Myc expression partially recapitulates their proliferation-
related phenotypes of increased growth, estrogen-independent proliferation and 
resistance to OHT and fulvestrant.  
 
DISCUSSION 
Clustered mutations in the ERα LBD occur in 20-40% of ERα positive metastatic breast 
cancers (7, 10, 39). While all metastatic ERα positive breast cancers display resistance 
to endocrine therapy and ultimately to standard chemotherapy, patients with tumors 
harboring the common ERαY537S and ERαD538G mutations exhibit 1-year and 6-month 
shorter median survival than patients whose metastatic tumors contain wild type ERα (18). 
To identify roles of these mutations, transient transfection，CRISPR/Cas9 and other 
techniques were used to express ERα LBD mutations in breast cancer cells (7, 9, 13-15).  
Transcriptome level studies of cells bearing ESR1 mutations are limited and were either 
restricted to a single mutation (13), or lack extensive functional analysis (14). We 
compared T47D cells harboring ERαY537S and ERαD538G mutations and parental cells 
at two time points and confirmed several key observations with the MCF7 dataset. 
Surprisingly, the MDS results show that the mutations are not simply constitutively active 
ERα, and instead exhibit unique gene expression patterns. 
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These ERα LBD mutations occur primarily after patients have received endocrine 
therapy (7, 9, 10, 40). Very recently, naturally occurring ESR1 Y537C and Y537S 
mutations were identified by selection in long-term-estrogen-deprived MCF7 cells (12). 
Taken together, these studies, and the data we present, show that the changes in the 
Y537 and D538 ESR1 mutations are sufficient to confer on breast cancer cells partial 
resistance to antiestrogens and estrogen-independent gene expression and cell 
proliferation. Across different clones, different parental cell lines and zygosity status, 
expression of most mRNAs tested exhibited a higher basal level and lower estrogen 
response in ERY537S cells than in ERD538G cells. Compared to cells expressing 
ERαD538G, we (Fig. 5A) and others, observe increased antiestrogen resistance in cell 
lines expressing ERαY537S (11, 14). These data suggest enhanced estrogen-
independent gene expression in breast cancer cells expressing ERαY537S may confer 
unique properties that influence tumor behavior and response to therapy.  
 Previous studies focused almost entirely on proliferation-related properties of ESR1 
mutations. However, ESR1 mutations were detected at higher allele frequency in 
metastases than in the primary breast cancers (41, 42). To probe the role of ESR1 
mutations in metastasis-related properties we improved conventional transwell assays 
(32) which fail to detect invaded cells that partially recapitulate the metastasis-related 
property of cell dissociation from the membrane and reattachment at a second site. Using 
T47D, TYS and TDG cells that stably express luciferase and luciferase-expressing 
lentivirus in MCF7 cell lines, we used our invasion-dissociation-rebinding assay to 
quantitate both the number of invaded cells and the number of invaded cells that then 
dissociate from the membrane and rebind on the bottom of the well. In the in vitro 
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invasion-dissociation-rebinding assay, ERα mutations significantly increase both T47D 
cell invasion and dissociation-rebinding.  Consistent with the cell-based data, our in vivo 
data shows that the ERα mutations drive metastasis in otherwise non-metastatic T47D 
tumors. These data illustrate the value of the IDR assay (Fig. 6A). The dramatic increase 
in lung metastasis of TYS tumors compared to TDG tumors (Fig. 6E) was not predicted 
by the widely used Matrigel and collagen invasion assays, which show increased invasion 
by TDG cells (Fig. 6C). In contrast, the dissociation rebinding assay, which shows strongly 
increased dissociation and rebinding by the TYS cells compared to the TDG cells (Fig. 
6C), is much more consistent with the in vivo lung metastasis data (Fig. 6E). While 
metastasis is an exceptionally complex multi-step process that cannot be fully modeled 
with cell-based assays, our data shows that, compared to the traditional Matrigel invasion 
assay, our simple in vitro IDR assay explores cell properties that correlate with in vivo 
metastatic frequency. Thus, the IDR assay provides a useful in vitro model for 
investigation of metastasis-related properties. 
To identify pathways driving these aggressive phenotypes of ERα mutant cells, we 
performed GSEA using T47D and MCF7 RNAseq datasets. Compared to parental cells, 
Myc target genes were highly enriched in T47D and MCF7 mutant cells; other upregulated 
pathways like “E2F targets” and “G2M checkpoint” are tightly correlated with Myc 
expression. Myc directly induces expression of cell cycle regulators, including Cyclin D, 
Cyclin E and E2Fs (43, 44). Myc also promotes cell cycle progression by regulating CDK 
phosphorylation and antagonizing cell cycle inhibitor expression (45, 46). In estrogen-
deprived ERαY537S and ERαD538G cells, Myc was highly induced, suggesting Myc 
might play an important role in their E2-independent proliferation. Myc knockdown 
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demonstrated that Myc is necessary for E2-independent proliferation of the TYS and TDG 
cells. Constitutive Myc expression in E2-deprived T47D cells was sufficient to induce 
moderate E2-independent proliferation. Moreover, TYS and TDG cells developed 
estrogen-independent tumors in ovariectomized mice; Myc expression was highly 
elevated in these tumors. Myc overexpression in tumors has been correlated with cancer 
stemness, which leads to reduced responsiveness to anticancer drugs and increased 
metastatic potential (24, 25, 36). In breast cancer cells, overexpression of Myc and its 
downstream targets Cyclin E1 and Cyclin D1 results in decreased sensitivity to 
antiestrogens (47, 48). An analysis of Myc in 399 patients with ERα positive breast cancer 
showed that higher levels of Myc expression were associated with shorter relapse free 
survival (48). Notably, while these studies and our data demonstrate an important role for 
Myc in proliferation-related phenotypes and therapy resistance, Myc expression in T47D 
cells had no effect on metastasis-related invasion, dissociation and rebinding. 
In addition to Myc upregulation, these cell lines exhibit alterations in protective pathways 
associated with resistance to cell death. The UPR was upregulated in E2-treated T47D 
and MCF7 cells and in ERY537S and ERD538G mutants. UPR upregulation is 
consistent with our recent work demonstrating E2-activation of the anticipatory UPR in 
ER containing T47D and MCF7 breast cancer cells (49), in PEO4 ovarian cancer cells 
(50), and estrogen-independent UPR activation in TYS and TDG cells (11). Since 
increased expression of a UPR gene index was tightly correlated with reduced time to 
tumor recurrence, tamoxifen resistance and reduced survival (49), these pro-survival 
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Figure 2.1 Gene expression patterns in TYS and TDG cells. A Venn diagrams 
comparing genes with absolute fold change >2 and false discovery rate <0.05 in vehicle-
treated TYS and TDG cells. Up- and down-regulated genes were analyzed in two Venn 
diagrams. B Heatmap showing log counts per million (CPM) of genes that have CPM >1 




Figure 2.2 TYS and TDG cells exhibit unique gene expression patterns. A,B Venn 
diagrams comparing genes with absolute fold change >2 and false discovery rate (FDR) 
q-value <0.05 in T47D, TYS and TDG cells after 4h A and 24h B E2 treatment. C Heatmap 
showing log counts per million (CPM) of genes that have CPM >1 in at least 3 samples 
after 24h E2 treatment. D,E Multi-dimensional scaling (MDS) plot of RNAseq samples 4h 
D and 24h E after E2 addition. Similarities of gene expression patterns were calculated 
and mapped for T47D (T), TYS (Y) and TDG (D) cells treated with vehicle (V) or estrogen 
(E). Data from each of the three biological replicates is shown. F Real-time PCR analysis 
of GREB1, PGR, CXCL12, IL1R1, PI9 and EGR3 in T47D, TYS and TDG cells after 
addition of vehicle or E2 for 4h or 24h. (mean ± s.e.m., n=3). Different letters indicate a 
significant difference among groups (P<0.05) using one-way ANOVA followed by 




Figure 2.3 ERαY537S and ERαD538G mutations promote constitutive expression 
of ERα target genes. Real-time PCR analysis of GREB1, PGR, CXCL12, PI9, IL1R1 and 
EGR3 in T47D, and a second set of clonal cell lines, T47D-ERαY537S (clone 39) and 
T47D-ERαD538G (clone 28) that are distinct from TYS and and TDG cells, after addition 
of vehicle or E2 for 24 h (mean ± s.e.m., n=3). Different letters indicate a significant 







Figure 2.4 Gene expression patterns in MCF7, MCF7-Y537S and MCF7-D538G cells. 
A Real-time PCR analysis of GREB1, PGR, CXCL12, PI9, IL1R1 and EGR3 in MCF7, 
MCF7-Y537S and MCF7-D538G cells after addition of vehicle or E2 for 24 h. n=3 ± s.e.m.. 
The dramatic Fold Induction of PR mRNA is due to extremely low basal levels of PR 
mRNA in our estrogen starved MCF7 cells. Different letters indicate a significant 
difference among groups (P<0.05) using one-way ANOVA followed by Tukey’s post hoc 
test. B Western blot showing progesterone receptor (PR) levels following treatment of 
cells with vehicle or 1 nM E2 for 24h. C Multi-dimensional scaling (MDS) plot of RNAseq 
samples 24h after E2 addition. Similarities of gene expression patterns were calculated 
and mapped for MCF7 (M), MCF7-Y537S (Y) and MCF7-D538G (D) cells treated with 




Figure 2.5 ERαY537S and ERαD538G mutant cells exhibit estrogen-independent 
cell proliferation and partial resistance to antiestrogens. A MTS assay of T47D, TYS 
and TDG cells, grown 4 days in 10% CD-FBS, treated with the indicated concentrations 
of E2, OHT and fulvestrant/ICI. For each treatment condition, the data from TYS and TDG 
cells was significantly different from the corresponding T47D cell data (*** P<0.001). B 
MTS assay of T47D-ERαY537S (clone 39) and T47D-ERαD538G (clone 28) cells, grown 
in 10% CD-FBS, treated with the indicated concentrations of E2, OHT and fulvestrant/ICI. 
C MTS assay of MCF7, MCF7-Y537S and MCF7-D538G cells, grown in 1% CD-calf 
serum, treated with the indicated concentrations of E2, OHT and fulvestrant/ICI. A, B, C 
‘---’ denotes day 0 cell number, (2000 cells/well). The graph shows mean growth at day 
4 ± s.e.m (n=6). One-way ANOVA was used to evaluate statistical significance. ns, not 
significant. D Representative crystal violet staining images showing more TYS and TDG 
cells invaded through the collagen-coated membrane. E IDR assay of MCF7, MCF7-
Y537S and MCF7-D538G cells with matrigel-coated membranes and chambers. The data 
represents the percent of invaded cells that have dissociated from the membrane and 
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Figure 2.5 (cont.) rebound at the bottom of the well (IDR/Invaded Cells %) (mean ± s.e.m., 
n=5, letters denote significant differences between groups). F Representative BLI images 
of the mice with WT T47D cells + E2 pellets, TYS and TDG xenografts. One mouse from 
the T47D and one from TDG group died prior to ex vivo lung imaging. ‘D’ denotes the 
dead animals. These photographs were made using IVIS exposure times that allow 
visualization of differences between individual mice within each test group. For example, 
because of the higher light output of the TDG-Luc cells, a very short exposure was used 




Figure 2.6 ERα Y537S and D538G mutations increase breast cell invasiveness and 
promote a metastatic phenotype. A Schematic of the invasion-dissociation-rebinding 
(IDR) assay. B The upper panel illustrates measurement of total invaded cells and IDR 
(invaded then dissociated and rebound) cells. IDR assay of T47D, TYS and TDG cells 
with collagen- B or matrigel-coated C membranes and chambers (n=5). Cell number 
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Figure 2.6 (cont.) calculated from a standard curve of light units (luciferase activity) versus 
cell number for each cell line. D Ex vivo imaging of excised lungs from xenograft bearing 
mice. As shown in the High to Low spectrum band, white dots are not bioluminescent 
signals. E Quantification of the bioluminescent signal in the lung areas shown in Fig. 2D. 
Shown as mean flux ± s.e.m.. The fluxes of lung metastases were normalized for the 
emission efficiency determined by tumor flux/ tumor weight. Similar results were obtained 
when the data was calculated as lung flux/ primary breast tumor flux. * Indicates a 
significant difference among groups using student t test. *P<0.05, **P<0.005, ***P<0.001. 














Figure 2.7 Estrogen upregulated pathways are constitutively activated in TYS and 
TDG cells. Gene set enrichment analysis (GSEA) using the ‘hallmark gene set’ as the 
reference dataset. The bar chart shows the normalized enrichment scores (NES) of 
pathways that are significantly up- or down-regulated in pair-wise comparisons between 
vehicle A 4h E2 B and 24h E2 C treated T47D, TYS and TDG cells and vehicle-treated 
T47D cells. All pathways had a false discovery rate q<0.0005 except those marked *, 






Figure 2.8 Estrogen upregulated pathways are constitutively activated in the MCF7-
Y537S and MCF7-D538G cells. Gene set enrichment analysis (GSEA) using the 
‘hallmark gene set’ as the reference dataset. The bar chart shows the normalized 
enrichment scores (NES) of pathways that are significantly up- or down-regulated in pair-
wise comparisons between vehicle A and 24h E2 B treated MCF7, MCF7-Y537S and 
MCF7-D538G cells and vehicle-treated MCF7 cells. All pathways had a false discovery 





Figure 2.9 Myc is overexpressed and contributes to antiestrogen resistance in TYS 
and TDG cells. A,B Bar charts showing the RNAseq mean fold change of Myc target 
genes in T47D, TYS and TDG cells after addition of E2 for 4h A or 24h B. C ChIP was 
performed in T47D, TYS and TDG cells treated with or without 500 nM fulvestrant/ICI for 
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Figure 2.9 (cont.) 10 min before adding 10 nM E2 for 30 min. Real-time PCR was used to 
analyze the enrichment of ERα binding sites at the Myc enhancer region.(51) D qRT- 
PCR analysis of Myc mRNA levels in T47D and mutant cells after treatment for 24h with 
1 nM E2, 1 nM E2 + 25 nM OHT, or 1 nM E2 + 25 nM fulvestrant/ICI. E qRT- PCR analysis 
of Myc mRNA levels in tumors induced with estrogen (T47D) or without added estrogen 
(TYS and TDG). C,D,E Mean ± s.e.m., n=3. Different letters indicate a significant 
difference among groups (p <0.05) using one-way ANOVA followed by Tukey’s post hoc 
test. F Western blot analysis of Myc, Cyclin E and E2F-2 levels in T47D, TYS and TDG 
cells after 24h in the indicated concentrations of vehicle, E2, OHT and fulvestrant. G 
Western blot analysis of Myc and E2F-2 protein levels following 24h treatment with 












Figure 2.10 Myc expression is directly regulated by ERα and is partially 
antiestrogen-resistant in TYS and TDG cells. A Proliferation of T47D, TYS and TDG 
cells treated with 100 nM non-coding (NC) or ERα SMARTpool siRNA for 24h followed 
by treatment with vehicle or 1 nM E2 for 96h (mean  s.e.m., n=6). B Western blot analysis 
of ERα and Myc protein levels after treatment of T47D, TYS and TDG cells with 100 nM 
non-coding (NC) or ERα SMARTpool siRNA followed by treatment with vehicle or 1 nM 
E2 for 24h. C,D Western blot analysis of Myc levels in T47D, T47D-ERαY537S (clone 39) 
and T47D-ERαD538G (clone 28) cells C and in MCF7, MCF7-Y537S and MCF7-D538G 
cells D after 24h treatment with vehicle, 1 nM E2, 50 nM OHT and 50 nM fulvestrant. E 
qRT-PCR analysis of E2F-2 and F Cyclin E mRNA levels in T47D and mutant cells after 
treatment with 1 nM E2, 1 nM E2 + 25 nM OHT, or 1 nM E2 + 25 nM ICI for 24h. * indicates 
a significant difference among groups using one-way ANOVA followed by Tukey’s post 





Figure 2.11 Myc is necessary and sufficient for estrogen-independent cell 
proliferation and antiestrogen resistance, but does not affect invasiveness. A 
Western blot showing Myc protein levels after treatment of T47D, TYS and TDG cells with 
100 nM non-coding (NC) or Myc SMARTpool siRNA for 24h, followed by treatment with 
vehicle or 1 nM E2 for 24h. B Proliferation of T47D, TYS and TDG cells treated with 100 
nM NC or Myc SMARTpool siRNA, followed by treatment with vehicle or 1 nM E2 for 96 
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Figure 2.11 (cont.) h (mean ± s.e.m., n=6). C Western blot showing Myc levels following 
treatment of cells with vehicle or 1 nM E2 with, or without, 1 μM JQ1 for 8h. D Proliferation 
of T47D, TYS and TDG cells treated with vehicle, E2, or E2 plus 0.5 or 1 μM JQ1 for 96 h 
(mean ± s.e.m., n=6). E Western blot showing ERα, Myc and Cyclin E levels in T47D, 
TYS and TDG cells treated with Myc-lentivirus or control luciferase-lentivirus, followed by 
the indicated concentrations of E2, OHT and ICI for 24h. F Proliferation of T47D, TYS and 
TDG cells, after transduction with Myc or control lentivirus containing medium for 24h, 
followed by treatment with the indicated concentrations of E2, OHT and ICI for 4 days. 
(mean ± s.e.m., n=6). B,D,F ‘•’ denotes cell number at day 0. C,E Myc protein levels were 
quantitated using a PhosphorImager and ImageQuant. B,D * indicates a significant 
difference among groups using one-way ANOVA followed by Tukey’s post hoc test. 
*P<0.05, **P<0.005, ***P<0.001. ns, not significant. F Different letters indicate a 
significant difference among groups (P<0.05) using one-way ANOVA followed by Tukey’s 
post hoc test. G,H IDR assay of T47D cells transduced with Myc-lentivirus or luciferase-
lentivirus with collagen- G or matrigel-coated H membrane and chamber (mean ± s.e.m., 
n=5). Cells were transduced with virus and after 1 day total invaded cells and cells that 
invaded, then dissociated and rebound (IDR) were measured using their luciferase 
















Software and reference genome used for RNAseq analysis. 
Software and Reference Version 
STAR aligner 2.5.1b 
Ensembl genome annotation GRch38.88 











Antibodies used in the immunoblot analysis. 
Target protein Catalog number Manufacturer 
c-Myc sc-40 Santa Cruz 
ERα sc-8002 Santa Cruz 
E2F-2 sc-9967 Santa Cruz 
Cyclin E sc-247 Santa Cruz 











Differentially regulated genes in T47D, TYS and TDG cells after estrogen treatment. 
Genes with fold change > 2 and false discovery rate < 0.05 were analyzed and numbers 
of genes in each category are shown. 
Cell/ Treatment 
Gene numbers 
Up Down Total 
T47D E2 4h 245 72 317 
T47D E2 24h 809 939 1748 
TYS  1469 2200 3669 
TYS E2 4h 1479 2191 3670 
TYS E2 24h 1373 1919 3292 
TDG 992 1600 2592 
TDG E2 4h  1070 1732 2802 
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ANTICIPATORY ACTIVATION OF THE UNFOLDED PROTEIN RESPONSE BY 
EPIDERMAL GROWTH FACTOR  





The onco-protein epidermal growth factor (EGF) initiates a cascade that includes 
activation of the ERK and AKT signaling pathways and alters gene expression. We 
describe a new action of EGF-EGF receptor (EGFR), rapid anticipatory activation of the 
endoplasmic reticulum stress sensor, the unfolded protein response (UPR). Within 2 min., 
EGF elicits EGFR dependent activation of phospholipase C γ (PLCγ), producing inositol 
triphosphate (IP3), which binds to IP3 receptor (IP3R), opening the endoplasmic reticulum 
IP3R Ca2+ channels, resulting in increased intracellular Ca2+. This calcium release leads 
to transient and moderate activation of the IRE1α and ATF6α arms of the UPR, resulting 
in induction of BiP chaperone.  Knockdown or inhibition of EGFR, PLCγ or IP3R blocks 
the increase in intracellular Ca2+. While blocking the increase in intracellular Ca2+ by 
locking the IP3R calcium channel with 2-APB had no effect on EGF activation of the ERK 
or AKT signaling pathways, it abolished the rapid EGF-mediated induction and repression 
of gene expression. Knockdown of ATF6α or XBP1, which regulate UPR-induced 
chaperone production, inhibited EGF stimulated cell proliferation. Supporting biological  
 
2 This chapter appeared in its entirety in Molecular and Cellular Endocrinology. Yu, L. et al. (2016) Anticipatory activation of the 
unfolded protein response by epidermal growth factor is required for immediate early gene expression and cell proliferation. Molecular 
and cellular endocrinology, 422, 31-41. Data in Figures 3.3 (C), 3.5 (A,B), 3.8 (A,B,H), 3.11 and Table 3.1 was obtained by Dr. Neal 
Andruska. Data in Figure 3.8 (C,D,E) was obtained by Dr. Xiaobin Zheng. 
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relevance, increased levels of EGF receptor during tumor progression were correlated 
with increased expression of the UPR gene signature. Anticipatory activation of the UPR 
is a new role for EGF. Since UPR activation occurs in <2 minutes, it is an initial cell 




Epidermal growth factor (EGF) stimulates cell proliferation and tumor growth by 
binding to a family of epidermal growth-factor receptors (EGFRs). The EGFR family 
consists of four members: ErbB1 (EGFR), ErbB2 (HER2/neu), ErbB3, and ErbB4 (1). 
Binding of EGF to EGFR leads to formation of activated EGFR dimer, which exhibits 
increased autophosphorylation. Phosphorylated EGFR activates several cell signaling 
pathways, including the ERK and AKT pathways and rapidly alters gene expression. The 
activated signaling pathways and altered gene expression program promote cell 
proliferation and invasion, and are anti-apoptotic (2). 
EGF receptor is overexpressed in many human cancers including lung, pancreatic, 
brain, bladder, and breast cancer (3-5). EGFR is expressed in most breast cancers and 
is overexpressed in ~50% of triple-negative (ER-, PR-, and HER2/neu-) breast cancers 
and in highly-aggressive invasive breast cancer (IBC) (6-8). EGFR overexpression is 
associated with larger tumors, poor differentiation, and poor clinical outcome (2, 9, 10). 
Activated EGFR reduces sensitivity to anticancer drugs. Although, responses to EGFR 
inhibitors given alone were modest (11-13), sustained inhibition of EGFR with erlotinib 
led to increased doxorubicin response and death of triple-negative breast tumors (14). 
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This suggests that EGFR inhibitors may enhance chemosensitivity of breast tumors to 
cytotoxic agents. 
     The ability of EGF-EGFR to reduce sensitivity to anticancer drugs suggested activated 
EGFR might alter responses to chemotherapy-induced stress by influencing the activity 
of stress response pathways. The sensor system for endoplasmic reticulum stress is the 
unfolded protein response. In the well-studied “reactive” mode of UPR activation, UPR 
sensors react to an excess of unfolded or misfolded protein, metabolic stress or 
anticancer drugs by activating signaling pathways that increase protein-folding capacity 
and reduce protein production (15, 16). Moderate activation of the UPR is protective. 
Consistent with the protective role of the UPR, a correlation between UPR activation and 
resistance to therapy has been described for several cancers (17-21). It was widely 
accepted that UPR activation in tumors arose by clonal evolution and selection of cells 
that survived in part because they responded to therapy-induced stress by activating the 
UPR (22, 23). In contrast to this well-known “reactive” mode of UPR activation, a little 
studied alternative mode of UPR activation termed “anticipatory” UPR activation occurs 
in the absence of endoplasmic reticulum stress (16). Anticipatory UPR activation was 
initially described in B-cells. Differentiation factors interleukin 4 and lipopolysaccharide 
induce UPR activation in B lymphocytes prior to increased immunoglobulin synthesis. 
Very recent studies demonstrate that estrogen in humans (24), ecdysone in insects (25, 
26) and human vascular endothelial growth factor (VEGF) (27) elicit biologically 
significant anticipatory activation of the UPR. Bioinformatic studies indicate that 
anticipatory estrogen activation of the UPR occurs early in breast cancer development, 
prior to detection and initiation of therapy (24).  
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     Many, but not all, mitogenic hormones elicit anticipatory activation of the UPR as an 
early event in the proliferation program. We therefore tested whether EGF elicits 
anticipatory activation of the UPR and whether rapid activation of the anticipatory UPR 
pathway is important for subsequent actions of EGF-EGFR. We demonstrate EGF-
EGFR-mediated rapid anticipatory activation of the UPR through activation of 
phospholipase C  (PLC), resulting in increased production of inositol triphosphate (IP3). 
The IP3 binds to and opens endoplasmic reticulum IP3 receptors (IP3R) leading to rapid 
efflux of calcium stored in the lumen of the endoplasmic reticulum into the cytosol. This 
activates the UPR, resulting in induction of the anti-apoptoptic chaperone 
BiP/GRP78/HSPA5 (28). Although intracellular calcium was increased in ~1 min., 
blocking the increase in intracellular calcium did not inhibit subsequent EGF-EGFR 
activation of the ERK and AKT signaling pathways. However, blocking the increase in 
intracellular calcium completely inhibited EGF-EGFR induction of pro-proliferation 
immediate early gene expression and reversed EGF-EGFR mediated down-regulation of 
pro-apoptotic genes. Moreover, knockdown of the chaperone-inducing arms of the UPR 
strongly inhibited EGF stimulated cell proliferation. Anticipatory activation of the UPR is a 
newly revealed early action of EGF-EGFR with very different effects on plasma 
membrane and nuclear EGF-EGFR-regulated pathways. 
 
MATERIALS AND METHODS 
Cell Culture 
MDA MB-468 cells were maintained in phenol-red free DMEM/F12, supplemented with 
10% fetal bovine serum ([FBS], Atlanta Biological, Atlanta, GA). MCF10A cells were 
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maintained in DMEM/F12, supplemented with 2% charcoal-dextran (cd)-stripped FBS. 
MCF10A cells were supplemented with 0.5 g/ml hydrocortisone, 10 g/ml insulin, 20 
ng/ml epidermal growth factor (EGF), and 0.1 g/ml cholera toxin. HCC1954 cells were 
maintained in RPMI1640, supplemented with 10% FBS. T47D cells were maintained in 
MEM, supplemented with 10% FBS. Estrogens were removed from the medium by 
maintaining T47D cells for at least three days in 10% charcoal dextran treated FBS (cd-
FBS), and cells were plated in MEM containing 10% cd-calf serum. 
 
Cell Proliferation Assays 
Cell proliferation assays were carried out as described (24, 29). Briefly, cells were plated 
in 96-well plates at the following densities: MDA MB-468 (2,000 cells/well), T47D (2,000 
cells/well), MCF10A (1,000 cells/well), and HCC-1954 (2,000 cells/well). Cell viability was 
determined using CellTiter 96® Aqueous One Solution Cell Proliferation Assay (MTS, 
Promega, WI). Cell number was determined from a standard curve of absorbance versus 
cell number for each cell line. 
 
Luciferase Assay 
Luciferase assay were as previously described (30). Hela cells were plated (300,000 
cells/well in 1 ml) in 6-well plates in 10% CD-CS 3 days before transfection. On the day 
of transfection, the medium was changed to 0.2 ml of Opti-MEM (Invitrogen). DNA and 
Lipofectamine 3000 (Invitrogen) were diluted in Opti-MEM. A total of 2500 ng of DNA 
(1260 ng of XBP1-Luc, 40 ng Renilla-Luc and 1200 ng IP3 phosphatase or PTZ carrier) 
was transfected into each well at a DNA:Lipofectamine 3000 ratio of 1:1. 24 h after 
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transfection, 20 ng/ml EGF was added and the cells were incubated for 24 h. Cells were 
then lysed in 100 μl of passive lysis buffer (Promega), and luciferase activity was 
determined using a Dual-Luciferase Reporter Assay (Promega #E1910). XBP1-Luc and 
Renilla-Luc plasmids were constructed and modified by our lab. The IP3 phosphatase 
plasmid was previously described (31), and was generously provided by Dr. Mark Shapiro 
(University of Texas Health Science Center).  
 
Western Blots 
Western blotting was carried out as previously described (2, 5). Briefly, whole cell extracts 
were prepared using RIPA lysis buffer (Millipore, CA) and mini protease inhibitor mixture 
(Roche Applied Science, Germany). Bound antibodies were detected using horseradish 
peroxidase-conjugated secondary antibodies and chemiluminescent immunodetection. 
The following antibodies from Cell Signaling Technology (MA) were used: Phospho-eIF2 
(Ser51) (#3398), eIF2 (#5324), Phospho-AKT (Thr308) (#13038P), AKT (#9272S) 
Phospho-p44/42 MAPK (#4370), p44/42 MAPK (#4695), BiP (#3177). Other antibodies 
used: pan-IP3R (sc-28613; Santa Cruz Biotechnology), ATF6 (Imgenex, CA), β-Actin 
(Sigma, Saint Louis, MO), and -Tubulin (Sigma, Saint Louis MO). 
 
qRT-PCR Analysis  
Cells were seeded into 6-well plates and grown to ~70% confluence. For EGF regulated 
gene expression assays, cells were washed two times with HEPES buffer (140 mM NaCl, 
4.7 mM KCl, 1.13 mM MgCl2, 10 mM HEPES, 10 mM Glucose, pH = 7.4) and then 
incubated in medium containing 100 nM 2-APB (Sigma, Saint Louis MO) or 10 μM UO126 
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for 5 minutes at 37 °C before EGF treatment. Cells were treated with a saturating 
concentration (20 ng/ml) or a sub-saturating concentration (2 ng/ml) of EGF or vehicle-
control for the indicated times, and RNA was extracted and purified using the Qiagen 
RNeasy kit. cDNA was prepared from 1 g of RNA with M-MuLV reverse transcriptase 
from New England Biolabs. Diluted cDNA was used to perform quantitative RT-PCR using 
power SYBR® Green (Life technologies, NY) with actin as the internal control. 
 
siRNA Knockdowns 
siRNA knockdowns were performed using DharmaFECT1 Transfection Reagent and 100 
nM ON-TARGETplus non-targeting pool or SMARTpools for PLC (PLCG1) or pan-IP3R 
(GE Healthcare, UK). The pan-IP3R SmartPool consisted of three individual SmartPools, 
each at 33 nM, directed against each isoform of the IP3R (ITPR1, ITPR2, and ITPR3). 
 
Calcium Imaging 
A calcium-sensitive dye, Fluo-4 AM, was used to measure cytoplasmic Ca2+. Cells were 
grown on 35 mm fluorodish plates (World Precision Instruments, FL) for two days prior to 
experiments. Cells were loaded with 5 M Fluo-4 AM (Life Technologies, NY) in calcium 
free HEPES buffer for 30 minutes at 37oC. Cells were washed three times with the buffer 
and incubated for 10 minutes with either 2 mM CaCl2 or without CaCl2. Fluoresence was 
monitored for one minute to determine basal fluorescence intensity, and then the 
appropriate treatment was added. Measurements were taken using a Zeiss LSM 700 
confocal microscope with a Plan-Four 20X objective (N.A. = 0.8) and 488-nM laser 
excitation (7% power). Images were obtained by monitoring fluorescence emission at 525 
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MDA MB-468 cells were incubated for 10 minutes in 20 ng/ml EGF or vehicle. Intracellular 
IP3 levels were determined by extracting cell lysate, and determining IP3 levels in an 
assay based on competitive binding to a recombinant IP3R fragment (Perkin Elmer, MA) 
that was saturated with 3H-IP3. Unlabeled IP3 was used as a standard for the assays. 




All data is reported as mean ± S.E.M. A two-tailed student’s t-test is used for comparisons 
between groups. One-way ANOVA followed by LSD or Tukey’s post hoc test is used for 
multiple comparisons with SPSS 13.0 for Windows (SPSS, Chicago, IL, USA). 
Significance was established when p < 0.05.  
 
RESULTS 
EGF Activates the UPR in Breast Cancer Cells 
To assess whether EGF rapidly activates the UPR, we selected a diverse set of 
breast cancer cell lines with different expression levels of EGFR protein and different 
effects of EGF on cell proliferation. (i) ER+ T47D breast cancer cells express low levels 
of EGFR, and are EGF-dependent for cell proliferation (Fig. 1A) (29, 32); (ii) MCF10A 
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pre-tumorigenic breast cells grossly overexpress EGFR, express minimal levels of 
HER2/neu and are fully dependent on EGF for proliferation (Fig 1B); (iii) triple-negative 
MDA MB-468 breast cancer cells, grossly overexpress EGFR through gene amplification, 
and EGF does not stimulate their proliferation (Fig. 1C); and (iv) ER- HCC-1954 breast 
cancer cells, which overexpress equal amounts of EGFR and HER2/neu, and do not 
depend on EGF for cell proliferation (Fig. 1D) (33, 34). 
To assess whether EGF activates the UPR, we focused on markers indicative of 
activation of each arm of the UPR (Fig. 2). The UPR regulates protein production by 
autophosphorylation of the transmembrane kinase, PERK (16, 35). p-PERK 
phosphorylates eukaryotic initiation factor 2 (eIF2), resulting in transient inhibition of 
protein synthesis. The other UPR arms initiate with activation of the transcription factor 
ATF6, leading to increased chaperone production and activation of the ER splicing factor 
IRE1, which splices the transcription factor XBP1, leading to production of active 
spliced-XBP1, increased protein folding capacity and altered mRNA decay and translation 
(16, 35). We first assessed whether EGF could activate the IRE1 arm of the UPR. In 
response to UPR activation, active spliced-XBP1 (sp-XBP1) enters the nucleus and 
regulates expression of UPR targets (Fig. 2A). EGF rapidly activated the IRE1 arm of 
the UPR, as shown by increased splicing of XBP1 mRNA in T47D, MDA MB-468, HCC-
1954 and MCF10A breast cancer cells (Fig. 3A).  Pre-treating cells with the EGFR 
inhibitor, erlotinib, blocked EGF-induction of sp-XBP1 mRNA (Fig. 3B), demonstrating 
that activation of the IRE1 arm of the UPR is dependent on activation of EGFR. Although 
our primary focus was on EGF in breast cancer cells, EGF also activated the UPR in 
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HeLa cervical cancer cells as shown by activation of a transfected luciferase reporter 
activated by sp-XBP1 (Fig. 4). 
We next evaluated whether EGF activates the ATF6 arm of the UPR. ATF6 
activation involves release from the ER and transport to the Golgi apparatus where 
ATF6 undergoes proteolytic cleavage to form active p50-ATF6 (Fig. 2B) (16, 35, 36). 
Supporting rapid EGF activation the ATF6 arm of the UPR, EGF modestly increased 
proteolysis of ATF6 (Fig. 3C, Fig. 5B), which was blocked by pre-treatment with erolitinib 
(Fig. 5A). 
p50-ATF6 regulates induction of BiP and other UPR-regulated chaperones (36, 37). 
Inducing BiP increases ER protein folding capacity, contributing to resolution of the stress, 
and helps reverse UPR activation (38). Overexpression of BiP is linked to a poor 
prognosis in breast and other cancers (39). EGF rapidly induced BiP mRNA in T47D, 
MDA MB-468, HCC-1954 and MCF10A breast cancer cells (Fig. 3D), leading to increases 
in BiP protein levels (Fig. 3F). Consistent with BiP induction being dependent on 
activation of EGFR, pre-treating MDA MB-468 cells with erlotinib blocked EGF-induction 
of BiP mRNA (Fig. 3E). While induction of BiP mRNA led to increases in BiP protein in 
T47D and MDA MB-468 cells (Fig. 3F), EGF did not increase BiP protein levels in pre-
tumorigenic MCF10A cells (Fig. 5C). XBP1 can directly interact with and activate estrogen 
receptor  (40). Although the mechanism by which XBP1-ER interaction might impact 
translation is unclear, this may provide an explanation for the different levels of BiP 
expression in estrogen receptor positive T47D cells and estrogen receptor negative MCF 
10A cells. Alternatively, since BiP expression is elevated in breast cancer cells relative to 
surrounding normal tissue (41), the different stages of tumor development in non-
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tumorigenic MCF10A cells compared to tumorigenic  T47D and MDA-MB-468 cells may 
play a role. 
Inducing BiP helps protect cancer cells against protein-misfolding and other forms of 
UPR stress (24). Extensive and sustained activation of the UPR is toxic. This enabled us 
to test whether prior exposure of MDA MB-468 cells to EGF or to a low concentration of 
the UPR activator tunicamycin (TUN) could alter the concentration of TUN required to 
subsequently induce cell death. Pretreating cells with EGF or with TUN increased the 
concentration of TUN required to induce cell death by ~2 fold (Fig. 6). 
We next assessed whether EGF activates the PERK arm of the UPR. Activated 
PERK induces increased eIF2 phosphorylation (Fig. 2C). EGF induced a rapid increase 
in phosphorylation of eIF2 (Fig. 7A, B). Phosphorylation of eIF2 leads to preferential 
translation of ATF4 mRNA, and we observed a moderate and transient increase in ATF4 
protein expression. In contrast, the toxic UPR activator, tunicamycin (TUN) robustly 
induced ATF4 (Fig. 7C, D). Because mild and transient activation of the PERK arm of the 
UPR does not induce the proapoptotic protein CHOP (24), CHOP was not induced by the 
EGF stimulated ATF4 (Fig. 7E, F). This data demonstrates that EGF elicits moderate and 
transient activation of all three arms of the UPR. 
 
EGF Activates the UPR through a PLC-dependent Mechanism 
Because the pathway is activated in less than 2 min., it was unlikely that 
accumulation of misfolded protein or other forms of EGF-induced stress triggered UPR 
activation. We recently identified a different anticipatory pathway of UPR activation in 
which the estrogen, 17-estradiol, bound to estrogen receptor  rapidly activates 
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phospholipase C  (PLC). Active phosphorylated plasma membrane PLC, hydrolyzes 
PIP2 to diacylglycerol (DAG) and inositol 1, 4, 5-triphosphate (IP3). The IP3 binds to 
endoplasmic reticulum IP3 receptors opening the IP3R Ca2+ channels and allowing efflux 
of Ca2+ stored in the lumen of the endoplasmic reticulum into the cytosol. This activates 
the UPR. Consistent with a role for Ca2+ efflux in UPR activation, the well-studied UPR 
activator thapsigargin rapidly activates the UPR by depleting Ca2+ stores in the lumen of 
the ER and increasing cytosol Ca2+ (24). Although EGF has been reported to activate 
PLC, the consequences of PLC activation were unknown (42). We therefore evaluated 
the role of Ca2+ release in EGF activation of the UPR. 
EGF induced rapid phosphorylation and activation of PLC in T47D and MDA MB-
468 breast cancer cells (Fig. 8A, B). EGF-mediated phosphorylation of PLC was blocked 
by pre-treatment with the EGFR inhibitor, erlotinib (Fig. 8A, B). PLC activation rapidly 
induced IP3 (Fig. 8C). 
To assess changes in the level of intracellular Ca2+, we used the calcium sensitive 
dye Fluo-4 AM. In the absence of extracellular Ca2+, EGF elicited a transient increase in 
fluorescence in MDA MB-468 cells (Fig. 8D). Since the increase in cytosol Ca2+ occurs in 
the absence of extracellular Ca2+, this suggested that the source of intracellular Ca2+ was 
the Ca2+ stored in the lumen of the endoplasmic reticulum. To identify the Ca2+ channels 
responsible for promoting the release of Ca2+ from the ER, we assessed whether the 
EGFR inhibitor erlotinib or 2-APB, which locks the IP3R Ca2+ channel, blocks the EGF-
mediated increase in cytosol Ca2+. Pre-treatment of MDA MB-468 cells with erlotinib, or 
with 2-APB, followed by EGF, blocked the increase in intracellular Ca2+ (Fig. 8D, E). To 
further confirm that PLC activation is required for EGF to activate the UPR, we performed 
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siRNA knockdown of PLC, and assessed whether EGF was still capable of activating 
the UPR and inducing the widely used surrogate marker for UPR activation, the 
chaperone BiP. Knockdown of PLC blocked phosphorylation of eIF2 and induction of 
BiP (Fig. 8F, G). Similarly, knockdown of IP3Rs blocked EGF-induction of BiP protein (Fig. 
8H). These data demonstrate that PLC activation, resulting in opening of the ER IP3 
receptor, mediates transient EGF activation of the UPR. (Pathway: EGF-EGFR-p (active) 
→ p-PLC (active) → IP3→ IP3:IP3R (open)→ Ca2+→ UPR (activated)→ BiP). 
 
Activation of the Anticipatory UPR Pathway is Required for EGF-EGFR-mediated 
Gene Expression and is Important for Cell Proliferation 
The EGF-EGFR mediated anticipatory pathway of UPR activation can be divided into 
a rapid early segment that involves activation of PLC, increased IP3, opening of the IP3R 
calcium channel and increased intracellular calcium and a late segment that involves 
activation of the 3 arms of the UPR and induction of BiP chaperone. Since the EGF 
induced increase in intracellular Ca2+ occurs in ~1 min. (Fig. 8D, E), it may precede other 
actions of EGF. We therefore tested whether the increase in intracellular calcium is 
important in subsequent rapid effects of EGF. These rapid pathways include rapid 
activation of the ERK and AKT signaling pathways and induction of pro-proliferation 
immediate early genes and rapid repression of pro-apoptotic genes. EGF-EGFR induction 
of immediate early genes, EGR1 and Fos is thought to play a role in EGF-mediated cell 
proliferation (38, 43). To test whether the extremely rapid increase in intracellular Ca2+ is 
important for subsequent EGF induction of EGR1 and Fos, we used sub-saturating 
biologically relevant concentrations of EGF. Fos and EGR1 mRNAs were robustly (>10 
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fold) induced after only 20 min. of EGF treatment. Blocking the EGF mediated increase 
in intracellular calcium with 2-APB completely blocked EGF induction of EGR1 and Fos 
mRNAs (Fig. 9A). Since 2-APB also prevents EGF-mediated down-regulation of the pro-
apoptotic BIK and BIM mRNAs (Fig. 9B), 2-APB is acting as a selective modulator of 
EGF-mediated gene expression and not as a general inhibitor of transcription. As 
expected, inhibition of ERK signaling with the ERK inhibitor UO1026 also blocked EGF-
induction of Fos and EGR1 mRNAs (Fig. 9A). To test whether elevated intracellular 
calcium was stimulating ERK activation (44), and activated ERK then induced immediate 
early gene expression, we examined the effect of 2-APB on rapid EGF activation of the 
ERK and AKT signaling pathways. Under the same conditions used in the gene 
expression experiment, 2-APB did not inhibit rapid and robust EGF activation of the ERK 
and AKT (protein kinase B) signaling pathways (Fig. 9C). Since 2-APB did not block EGF 
activation of the ERK pathway, the elevated level of intracellular calcium is a previously 
undescribed independent regulator of EGF-induced gene expression that works together 
with ERK activation to regulate immediate early gene expression. 
UPR-induced-chaperones, like BiP/GRP78, are thought to be important for cell 
proliferation (45, 46). We therefore evaluated the effect of UPR activation in EGF 
stimulated proliferation of T47D cells. Activation of the ATF6α and IRE1α arms of the 
UPR induces chaperone production. However, the IRE1α arm of the UPR also play a role 
in mRNA decay and JNK mediated apoptosis (47). To dissect out the role of chaperone 
induction, instead of carrying out an IRE1α knockdown, we knocked down XBP1 which 
encodes the spliced XBP1 transcription factor when cleaved by the activated IRE1α. 
Compared to the control siRNA, knockdown of the XBP1 arm of the UPR produced a 
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highly significant 28% decline in EGF stimulated cell proliferation, while ATF6 knockdown 
produced a 35% decline (Fig. 9D). These data indicate that EGF induced UPR activation 
and the subsequent chaperone production plays an important role in EGF stimulated cell 
proliferation. 
 
Overexpression of EGFR and HER2/neu is Correlated with Increased UPR 
Activation 
The UPR plays an important role in cancer cell migration, metastasis and resistance 
to therapy-induced apoptosis. Consistent with a role for the anticipatory UPR pathway in 
the oncogenic actions of EGF, a recent report found that PLC signaling was important 
for EGF to induce an aggressive pro-metastastic phenotype (48). We therefore evaluated 
whether overexpression of HER2/neu or EGFR was correlated with increased activation 
of the UPR in tumors by evaluating a UPR gene signature (24) in several publically 
available patient tumor cohorts. 
To assess UPR activity early in EGFR+ breast cancer development, we compared 
EGF receptor family member expression level and UPR pathway activity in samples of 
histologically normal breast epithelium, ductal carcinoma in situ (DCIS) and invasive 
ductal carcinoma (IDC). Compared with normal epithelium, DCIS and IDC samples 
displayed elevated levels of EGF receptor family members mRNA (Fig. 11A). Additionally, 
DCIS and IDC samples displayed elevated markers of UPR activation. Besides the 
classic UPR maker genes, additional UPR related genes were correlated with increased 
expression of EGFR. Specifically, SERP1 mRNA, a marker for IRE1α activation (49), 
TRIB3, which is a marker of PERK activation (50), and BiP chaperone, which is a marker 
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of ATF6α activation (Fig. 11B). These data suggest that UPR activation is correlated with 
EGF receptor family member expression. 
Using data from an independent cohort of 114 ER- breast cancers, we explored whether 
the expression of HER2 mRNA correlates with the expression of UPR genes. The 
expression of several UPR genes displayed highly significant correlation with the 
expression of HER2 genes (Table 1). 
 
DISCUSSION 
Cancer progression is often correlated with increased protein synthesis and poor 
glucose and oxygen supply in the microenvironment (51, 52). In response to these 
different intrinsic and extrinsic stresses, cancer cells activate the UPR pathway. UPR 
activation has been described in several human tumors including myeloma (53), 
lymphoma (54) and carcinoma of the breast (55). The role of UPR activation in resistance 
of breast cancer and other tumors to tamoxifen and other therapeutics has been 
extensively studied (23). XBP1 is upregulated in antiestrogen resistant breast cancer cells 
(56). It interacts with and regulates the activity of estrogen receptor (40, 57), NFκB (58) 
and apoptosis related proteins (59); this may contribute to drug resistance in these cells. 
Induction of BiP and other chaperones may also play a role in this protective UPR 
activation (49).  
These studies have focused on the reactive mode of UPR activation in which cells 
respond to stress by activating the UPR and, if moderate and transient, the UPR is 
protective (24, 60). In this reactive form of UPR activation, diverse stressors increase the 
level of unfolded or misfolded proteins in the lumen of the endoplasmic reticulum. This 
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activates sensors in the endoplasmic reticulum membrane that both sense the stress and 
activate the 3 major arms of the UPR (Fig. 2) (15, 16, 61, 62).  
Here we describe a fundamentally different type of very rapid UPR activation that 
anticipates future needs and occurs in the absence of cell stress or accumulation of 
unfolded proteins. In less than 2 minutes EGF triggers PLC-mediated opening of 
endoplasmic reticulum IP3R calcium channels and release of Ca2+ into the cytosol. This 
increase in cytosol Ca2+ stimulates activation of all three arms of the UPR. Anticipatory 
activation of the UPR is a newly identified common pathway shared by several mitogenic 
hormones. We suggest this newly unveiled pathway is used by many, but not all, 
mitogenic hormones to prepare cells for the increased protein folding load that will occur 
during subsequent hormone-stimulated cell proliferation.  Although this pathway is 
conserved from peptide hormones to steroid hormones, there are important differences 
in the activation mechanisms. VEGF induced UPR activation is not inhibited by blocking 
the ER calcium signal (27). However, EGF mediated activation of the UPR is totally 
dependent on IP3 mediated calcium release from the ER.  
Supporting biological relevance of the UPR pathway, EGFR levels and expression 
levels of UPR related genes were strongly correlated in samples from 114 ER negative 
breast cancers. Moreover, there was a parallel increase in EGFR content and UPR gene 
index components as cells progress from normal mammary epithelial cells to DCIS and 
then to IDC. Thus the EGF induced anticipatory UPR pathway not only facilitates tumor 
cell proliferation but likely also helps protect cancer cells against subsequent apoptosis 
induced by hypoxia, nutrient deprivation and therapy. Since hypoxia, nutrient deprivation 
and therapy can all stimulate reactive UPR activation, the anticipatory and reactive modes 
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of UPR activation lead to UPR engagement throughout the entire cycle of tumor 
development and therapy. 
Since a key feature of rapid anticipatory activation of the UPR is an increase in 
cytosolic calcium, we explored the effect of blocking this increase on well-known actions 
of EGF-EGFR. The mitogenic action of EGF is mediated in part by regulation of immediate 
early gene expression. Two major EGF-induced immediate early genes, c-fos and egr1 
encode transcription factors important for cell cycle progression (63, 64). Rapid (5-30 min) 
EGF-EGFR activation of the ERK signaling pathway is essential for early gene expression 
(Fig. 9A and 10) (43). Cytosolic calcium levels play an important role in regulating ERK 
activation (65, 66). Moreover a massive increase in cytosol calcium due to strong and 
sustained cytotoxic UPR activation is sufficient to activate the ERK pathway (44). 
However, blocking the transient and moderate increase in cytosol Ca2+ induced by EGF-
EGFR activation of the protective anticipatory UPR pathway did not inhibit EGF-EGFR 
activation of the ERK or AKT signaling pathways (Fig.9 and 10). Since blocking the EGF-
induced increase in cytosol Ca2+ abolished induction and repression of gene expression 
by EGF, the anticipatory UPR pathway is not regulating immediate early gene expression 
by controlling ERK activation. ERK activation and the elevated calcium resulting from 
activation of the early stages of the anticipatory UPR pathway are independent EGF 
activated pathways that converge at the level of immediate early gene expression. Since 
2-APB blocks EGF-induced immediate early gene expression without affecting EGF 
activation of the ERK and AKT signaling pathways, 2-APB represents a useful new probe 
for dissecting the roles of immediate early gene expression and ERK and AKT activation 
in downstream actions of EGF. In contrast to 2-APB, the equally useful simultaneous 
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RNAi knockdown of all 3 functionally overlapping, but non-homologous, endoplasmic 
reticulum IP3R channels (Fig. 8H) is technically challenging and has rarely been reported. 
        Accumulating evidence suggests a role for UPR chaperones in regulation of cell 
proliferation. One of the most abundant and well characterized UPR-induced chaperones, 
GRP78/BiP, influences proliferation of embryonic cells (46). In a GRP78 heterozygous 
mice model where the level of BiP was reduced by about half, growth of breast tumors 
was significantly reduced (45). These results suggest UPR chaperones have functions 
other than facilitating protein folding within the ER. Using siRNA, we knocked down the 
major UPR chaperone producing pathways, the XBP1 and ATF6 arms (Fig. 2 and 12), 
and significantly inhibited EGF stimulated cancer cell proliferation (Fig. 9D).  
These results indicate that the EGF induced anticipatory UPR pathway facilitates 
EGF stimulated cell proliferation in at least two ways. First, it releases calcium from 
endoplasmic reticulum stores and cooperates with the ERK signaling pathway to regulate 
immediate early gene expression. Second, it increases UPR chaperone production, which 
facilitates EGF stimulated cell proliferation.  
Our studies add a new dimension to the cascade of events that occur when a cell is 









FIGURES AND TABLE 
 
Figure 3.1 Effects of EGF on proliferation of breast cancer cell lines. Effects of EGF 
on proliferation of (A) T47D breast cancer cells, (B) pre-tumorigenic MCF10A cells, (C) 
MDA MB-468 breast cancer cells, and (D) HCC1954 breast cancer cells. “•” denotes cell 





Figure 3.2 Endoplasmic reticulum (ER) stress activates the three arms of the UPR. 
(A) ER stress leads to the oligomerization, auto-phosphorylation, and activation of IRE1. 
Activated IRE1 has endonuclease activity and removes an intron from full-length XBP1 
(fl-XBP1) mRNA, producing spliced-XBP1 (sp-XBP1) mRNA. The translation product of 
sp-XBP1 increases lipid synthesis to expand ER capacity, induces ER-associated 
degradation (ERAD) genes to increase turnover of misfolded proteins. ERDJ, BiP and 
SERP1 are induced by sp-XBP1 expression. (B) ER stress promotes the translocation 
ATF6α, a transmembrane protein, from the ER to the Golgi apparatus. ATF6α is cleaved 
in the Golgi apparatus by two proteases and the cytosolic fragment (p50-ATF6) is 
released after cleavage. p50-ATF6 increases protein-folding capacity of the ER by 
inducing BiP, GRP94, and other ER chaperones. (C) UPR activation leads to the 
oligomerization, auto-phosphorylation, and activation of the transmembrane kinase 
PERK. Phosphorylated PERK oligomer has kinase activity which phosphorylates 
eukaryotic initiation factor 2 (eIF2), leading to general inhibition of protein synthesis. 
However, prolonged activation of eIF2 increases translation of certain mRNAs, including 
the transcription factor, ATF4 (67). ATF4, acting as a transcription factor, induces the 
expression of CHOP, which induces GADD34 and several pro-apoptotic genes which 




Figure 3.3 EGF activates the IRE1 and ATF6 arms of the UPR and induces 
production of the chaperone, BiP. (A) qRT-PCR comparing the effect of EGF on sp-
XBP1 mRNA in T47D, MDA MB-468, HCC1954 and MCF10A cells after EGF treatment 
for 2 hours (n=3; -EGF set to 1). (B) qRT-PCR analysis of sp-XBP1 mRNA in MDA MB-
468 breast cancer cells after pre-treating MDA MB-468 cells with erlotinib or with DMSO-
vehicle for 30 minutes, following by treatment with EGF for 2 hours (n = 3; -EGF set to 1). 
(C) Western blot analysis showing full-length ATF6 (p90-ATF6) and cleaved-ATF6 
(p50-ATF6) in EGF-treated T47D breast cancer cells. The numbers below the gel 
indicate the ratio of p50-ATF6/β-actin. (D) qRT-PCR analysis of BiP mRNA in T47D, 
MDA MB-468, HCC1954 and MCF10A breast cell lines after treatment with EGF for 4 
hours (n = 3; -EGF set to 1). (E) qRT-PCR analysis of BiP mRNA in MDA MB-468 breast 
cancer cells after pre-treating MDA MB-468 cells with erlotinib or DMSO vehicle for 30 
minutes, following by treatment with EGF for 4 hours (n = 3; -EGF set to 1). (F) Western 
blot analysis of BiP protein levels in T47D, MDA MB-468 cells treated with EGF. The 
numbers below the gel are the ratio of BiP/β-actin. Data is the mean ± SEM (n = 3). 





Figure 3.4 EGF activation of UPR is mediated through IP3 induced calcium release. 
T47D cells were transfected with the indicated amounts of IP3 phosphatase, XBP1-
luciferse reporter and renilla luciferase internal standard as described in Experimental 
Procedures. The transfected cells were treated with EGF (20 ng/ml) or TUN (10 μg/ml) 
and luciferase activity was determined. The data shows relative levels of XBP1-firefly 
luciferase expression normalized to renilla luciferase expression. The experiment shows 
that IP3 phosphatase blocks EGF induced XBP1-Luciferase expression but has little effect 




Figure 3.5 EGF activates the UPR. (A) EGF activates the ATF6 arm of the UPR in 
MDA MB-468 breast cancer cells. The increase in the level of cleaved, active ATF6 
(p50-ATF6) demonstrates activation of the ATF6 arm of the UPR. (B) Effects of EGF 
on cleaved-ATF6 (p50-ATF6) and inactive, full-length ATF6 p90-ATF6 in non-
tumorigenic MCF10A cells. (C) Effects of EGF on induction of BiP protein in non-
tumorigenic MCF10A breast cells. In contrast to T47D and MDA MB-468 cells (see Figure 




Figure 3.6 Prior EGF activation of the UPR protects MDA MB-468 from subsequent 
stress.  MDA MB-468 cells were maintained in the presence of 20 ng/mL EGF, 250 ng/mL 
tunicamycin, or a vehicle control for 7 days prior to treating cells with the indicated 





Figure 3.7 EGF activates the PERK arm of the UPR. Western blot analysis showing p-
eIF2 levels and total eIF2 levels in ER+ T47D cells (A) and in MDA MB-468 cells (B) 
treated with EGF for the indicated times. The numbers below the gel are the ratio of p-
eIF2/-tubulin ratio. Western blot analysis of ATF4 levels following treatment of T47D 
cells (C) and MDA MB-468 cells (D) with EGF, or with the UPR activator tunicamycin. The 
numbers below the gel are the ratio of ATF4/β-actin. qRT-PCR analysis of CHOP mRNA 
following treatment of T47D cells (E) and MDA MB-468 cells (F) with EGF. Concentrations: 




Figure 3.8 EGF activates the UPR through PLC-mediated opening of the IP3R Ca2+ 
channels, leading to the release of Ca2+ from the ER into the cytosol, and UPR 
activation. Western blot analysis of p-PLC and total PLC protein levels after treatment 
of (A) T47D or (B) MDA MB-468 breast cancer cells with EGF or EGF + erlotinib. Cells 
were treated with either 10 M erlotinib or vehicle-control, followed by 20 ng/ml EGF for 
the indicated times. The numbers below the gel are the ratio of p-PLCγ/β-actin. (C) 
Quantitation of intracellular IP3 levels following treatment of MDA MB-468 cells for 10 min. 
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Figure 3.8 (cont.) with or without EGF (n=3). (D)  EGF increases intracellular calcium 
levels in MDA MB-468 breast cancer cells in medium lacking calcium (0 mM CaCl2). 
Visualization of intracellular Ca2+ using Fluo-4 AM. Color scale from basal Ca2+ to highest 
Ca2+: blue, green, red, white. (E) Graph depicts quantitation of cytosolic calcium levels in 
MDA MB-468 breast cancer cells pre-treated with either vehicle-control, the EGFR 
inhibitor, erlotinib, or the IP3R inhibitor, 2-amino propyl-benzoate (2-APB), followed by 
treatment with 20 ng/ml EGF in the absence of extracellular calcium (indicated by the 
black arrow, n = 10 cells). Calcium quantitation data is expressed as mean ± SE (n = 10). 
(F) Western blotting analysis of PLC, p-eIF2α and total eIF2α protein levels after 
treatment of T47D cells with 100 nM non-coding (NC) or PLC siRNA, followed by 
treatment with EGF (+EGF) or ethanol-vehicle (−EGF) for 30 minutes. (G) Western 
blotting analysis of PLC and BiP protein levels after treatment of T47D cells with 100 nM 
non-coding (NC) or PLC siRNA, followed by treatment with EGF (+EGF) or ethanol-
vehicle (−EGF) for 4 h. (H) siRNA knockdown of the three isoforms of the IP3R Ca2+ 
channel blocks EGF-induction of BiP protein in T47D breast cancer cells. Cells were 
treated with either 100 nM non-coding (NC) or IP3R siRNA SmartPool, followed by 
treatment with 20 ng/mL EGF for 4 hours. IP3R smartpool contained equal amounts of 
three individual SmartPools directed against each isoform of IP3R. Data is mean ± SEM 





Figure 3.9 EGF induced UPR activation is required for EGF regulated gene 
expression and cell proliferation. (A and B) qRT-PCR of the oncogene mRNAs EGR1 
and Fos and the pro-apoptotic mRNAs BIK and BIM in T47D cells pre-treated for 5 min. 
with ethanol, 2-APB or the ERK inhibitor UO126, then treated with 2 ng/ml EGF for 20 
min. (A), or 2 hours (B) (Ca2+-free medium; n=3, mean ±SEM). (C) Western blot analysis 
showing p-ERK levels and total ERK and p-AKT and total AKT levels in T47D cells treated 
with 2 ng/mL EGF with or without 2-APB pretreatment. (D) EGF stimulated proliferation 
of T47D breast cancer cells treated with 100 nM non-coding (NC), ATF6 or XBP1 siRNA 
SmartPool (n=6). Proliferation rates were normalized to cells treated with non-coding (NC) 
siRNA. *p<0.05; ***p<0.001. 












Figure 3.11 Increased expression of EGF receptors is correlated with increased 
expression of the UPR gene signature. Expression of (A) EGF receptors and (B) UPR 
sensors and UPR-regulated genes in samples from normal breast epithelial cells (n=5), 
ductal carcinoma in situ (n=9), and invasive ductal carcinoma (n=5). Normal epithelial 











Figure 3.12 siRNA knockdown reduces levels of XBP1 and ATF6α. (A and B) qRT-
PCR analysis of (A) XBP1 and (B) sp-XBP1 expression after treatment of T47D cells with 
100 nM non-coding (NC) or XBP1 siRNA SmartPool, followed by treatment with EGF 
(+EGF) or PBS vehicle ( − EGF) for 2 h. (C) Western blotting analysis of PLCγ, BiP and 
ATF6α protein levels after treatment of T47D cells with 100 nM non-coding (NC) or ATF6α 
















Table 3.1 Correlations between UPR-related mRNAs and ErbB2 mRNA levels in 
ERα- tumors 
Pathway Gene HUGO Name Her2/neu p-value  
PLCy PLCy PLCG1 0.339 8.2 x 10-4  
Calcium 
Channels 
IP3R2 ITPR2 -0.422 2.3  x 10-5  
IP3R3 ITPR3 0.500 <10-7  
XBP1 Arm of 
UPR 
XBP1 XBP1 0.600 <10-7  
SERP1 SERP1 0.235 0.012  
PERK Arm 
of UPR 
PERK EIF2AK3 0.476 1 x 10-7  
eIF2 EIF2S1 0.352 1.3 x 10
-4  
 TRIB3 0.468 2 x 10-7  
ATF4 ATF4 0.300 1.2 x 10-3  
 HERPUD1 0.271 3.6 x 10-3  
GADD34 PPP1R15A 0.257 5.9 x 10-3  
ATF6 Arm of 
UPR 
ATF6 ATF6 n.s. -  
BiP HSPA5 0.289 1.8 x 10-3  
GRP94 HSP90B1 0.231 0.014  
p58IPK DNAJC3 0.205 0.03  
 
Data from a cohort of 114 breast cancer patients (GSE20194). Spearman correlation 
coefficients and parametric p-values are shown in the table. “n.s.” indicates that no 













1. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. 
Nat Rev Cancer. 2012;12(8):553-63. 
2. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of 
epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 
2012;136(2):331-45. 
3. Herbst RS, Langer CJ, editors. Epidermal growth factor receptors as a target for cancer 
treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck 
cancers. Semin Oncol; 2002: Elsevier. 
4. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer 
progression. Exp Cell Res. 2003;284(1):99-110. 
5. Saxena R, Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast 
cancer: current status and future clinical perspective. Medicinal research reviews. 
2012;32(1):166-215. 
6. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-
negative breast cancer: clinical features and patterns of recurrence. Clinical cancer 
research : an official journal of the American Association for Cancer Research. 
2007;13(15 Pt 1):4429-34. 
7. Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H. Prognostic impact of human 
epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory 
breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer 
Registry. Breast cancer research : BCR. 2009;11(1):R9. 
94 
 
8. Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K, et al. EGFR 
amplification and lack of activating mutations in metaplastic breast carcinomas. The 
Journal of pathology. 2006;209(4):445-53. 
9. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-
factor receptor status as predictor of early recurrence of and death from breast cancer. 
Lancet. 1987;1(8547):1398-402. 
10. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related 
peptides and their receptors in human malignancies. Critical reviews in 
oncology/hematology. 1995;19(3):183-232. 
11. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, et al. Phase II and tumor 
pharmacodynamic study of gefitinib in patients with advanced breast cancer. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 
2005;23(23):5323-33. 
12. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of 
erlotinib in patients with locally advanced or metastatic breast cancer. Breast cancer 
research and treatment. 2009;115(1):115-21. 
13. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor 
receptor targeting in cancer. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 2005;23(11):2445-59. 
14. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, et al. Sequential 
application of anticancer drugs enhances cell death by rewiring apoptotic signaling 
networks. Cell. 2012;149(4):780-94. 
95 
 
15. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein 
response. Nature reviews Molecular cell biology. 2007;8(7):519-29. 
16. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic 
regulation. Science. 2012;334(6059):1081-6. 
17. Auf G, Jabouille A, Guérit S, Pineau R, Delugin M, Bouchecareilh M, et al. Inositol-
requiring enzyme 1α is a key regulator of angiogenesis and invasion in malignant glioma. 
Proc Natl Acad Sci. 2010;107(35):15553-8. 
18. Crozat A, Åman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding 
protein in human myxoid liposarcoma. Nature. 1993;363(6430):640-4. 
19. Nawrocki ST, Carew JS, Dunner K, Boise LH, Chiao PJ, Huang P, et al. Bortezomib 
inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress 
in human pancreatic cancer cells. Cancer Res. 2005;65(24):11510-9. 
20. Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K, et al. Activation of the 
ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible 
involvement of the ER stress pathway in hepatocarcinogenesis. Journal of hepatology. 
2003;38(5):605-14. 
21. Prabhu A, Sarcar B, Kahali S, Shan Y, Chinnaiyan P. Targeting the unfolded protein 
response in glioblastoma cells with the fusion protein EGF-SubA. PloS one. 
2012;7(12):e52265. 
22. Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer–an overview 
and update. Mol Cell Endocrinol. 2015. 
23. Clarke R, Cook KL. Unfolding the role of stress response signaling in endocrine 
resistant breast cancers. Frontiers in oncology. 2015;5. 
96 
 
24. Andruska N, Zheng X, Yang X, Helferich W, Shapiro D. Anticipatory estrogen 
activation of the unfolded protein response is linked to cell proliferation and poor survival 
in estrogen receptor α-positive breast cancer. Oncogene. 2014. 
25. Liu W, Cai M-J, Zheng C-C, Wang J-X, Zhao X-F. Phospholipase Cγ1 Connects the 
Cell Membrane Pathway to the Nuclear Receptor Pathway in Insect Steroid Hormone 
Signaling. J Biol Chem. 2014;289(19):13026-41. 
26. Dong D-J, Jing Y-P, Liu W, Wang J-X, Zhao X-F. The steroid hormone 20-
hydroxyecdysone upregulates Ste-20 family serine/threonine kinase Hippo to induce 
programmed cell death. J Biol Chem. 2015:jbc. M115. 643783. 
27. Karali E, Bellou S, Stellas D, Klinakis A, Murphy C, Fotsis T. VEGF Signals through 
ATF6 and PERK to Promote Endothelial Cell Survival and Angiogenesis in the Absence 
of ER Stress. Mol Cell. 2014;54(4):559-72. 
28. Lee AS. Glucose-regulated proteins in cancer: molecular mechanisms and 
therapeutic potential. Nat Rev Cancer. 2014;14(4):263-76. 
29. Andruska ND, Zheng X, Yang X, Mao C, Cherian MM, Mahapatra L, et al. Estrogen 
receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and 
induces tumor regression. Proc Natl Acad Sci. 2015;112(15):4737-42. 
30. Cherian MT, Wilson EM, Shapiro DJ. A competitive inhibitor that reduces recruitment 
of androgen receptor to androgen-responsive genes. J Biol Chem. 2012;287(28):23368-
80. 
31. Hernandez CC, Zaika O, Tolstykh GP, Shapiro MS. Regulation of neural KCNQ 
channels: signalling pathways, structural motifs and functional implications. The Journal 
of physiology. 2008;586(7):1811-21. 
97 
 
32. Pattarozzi A, Gatti M, Barbieri F, Würth R, Porcile C, Lunardi G, et al. 17β-Estradiol 
promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated 
epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol 
Pharmacol. 2008;73(1):191-202. 
33. Sahin Ö, Löbke C, Korf U, Appelhans H, Sültmann H, Poustka A, et al. Combinatorial 
RNAi for quantitative protein network analysis. Proc Natl Acad Sci. 2007;104(16):6579-
84. 
34. Lin H, Hsieh F, Song H, Lin J. Elevated phosphorylation and activation of PDK-1/AKT 
pathway in human breast cancer. Br J Cancer. 2005;93(12):1372-81. 
35. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein 
response. Nat Rev Mol Cell Biol. 2007;8(7):519-29. 
36. Wu J, Rutkowski DT, Dubois M, Swathirajan J, Saunders T, Wang J, et al. ATF6alpha 
optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. 
Dev Cell. 2007;13(3):351-64. 
37. Okada T, Yoshida H, Akazawa R, Negishi M, Mori K. Distinct roles of activating 
transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like 
endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded 
protein response. The Biochemical journal. 2002;366(Pt 2):585-94. 
38. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer 
Res. 2007;67(8):3496-9. 
39. Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded 




40. Ding L, Yan J, Zhu J, Zhong H, Lu Q, Wang Z, et al. Ligand‑independent activation of 
estrogen receptor α by XBP‑1. Nucleic Acids Res. 2003;31(18):5266-74. 
41. Cook KL, Shajahan AN, Wärri A, Jin L, Hilakivi-Clarke LA, Clarke R. Glucose-
regulated protein 78 controls cross-talk between apoptosis and autophagy to determine 
antiestrogen responsiveness. Cancer Res. 2012;72(13):3337-49. 
42. Margolis B, Bellot F, Honegger A, Ullrich A, Schlessinger J, Zilberstein A. Tyrosine 
kinase activity is essential for the association of phospholipase C-gamma with the 
epidermal growth factor receptor. Mol Cell Biol. 1990;10(2):435-41. 
43. Murphy LO, Smith S, Chen R-H, Fingar DC, Blenis J. Molecular interpretation of ERK 
signal duration by immediate early gene products. Nat Cell Biol. 2002;4(8):556-64. 
44. Chao T, Byron K, Lee K, Villereal M, Rosner MR. Activation of MAP kinases by 
calcium-dependent and calcium-independent pathways. Stimulation by thapsigargin and 
epidermal growth factor. J Biol Chem. 1992;267(28):19876-83. 
45. Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, et al. Critical role of the stress chaperone 
GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced 
mammary tumor development. Cancer Res. 2008;68(2):498-505. 
46. Luo S, Mao C, Lee B, Lee AS. GRP78/BiP is required for cell proliferation and 
protecting the inner cell mass from apoptosis during early mouse embryonic development. 
Mol Cell Biol. 2006;26(15):5688-97. 
47. Chen Y, Brandizzi F. IRE1: ER stress sensor and cell fate executor. Trends Cell Biol. 
2013;23(11):547-55. 
48. Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zanker KS, et al. 
Induction of cancer cell migration by epidermal growth factor is initiated by specific 
99 
 
phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology. 
2002;16(13):1823-5. 
49. Lee A-H, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic 
reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol. 
2003;23(21):7448-59. 
50. Bromati CR, Lellis-Santos C, Yamanaka TS, Nogueira TC, Leonelli M, Caperuto LC, 
et al. UPR induces transient burst of apoptosis in islets of early lactating rats through 
reduced AKT phosphorylation via ATF4/CHOP stimulation of TRB3 expression. American 
Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 
2011;300(1):R92-R100. 
51. Ruggero D. Translational control in cancer etiology. Cold Spring Harbor perspectives 
in biology. 2013;5(2):a012336. 
52. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev 
Cancer. 2004;4(6):437-47. 
53. Lee A-H, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the 
unfolded protein response in myeloma cells. Proc Natl Acad Sci. 2003;100(17):9946-51. 
54. Jenner RG, Maillard K, Cattini N, Weiss RA, Boshoff C, Wooster R, et al. Kaposi's 
sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell 
gene expression profile. Proc Natl Acad Sci. 2003;100(18):10399-404. 
55. Lee E, Nichols P, Spicer D, Groshen S, Mimi CY, Lee AS. GRP78 as a novel predictor 
of responsiveness to chemotherapy in breast cancer. Cancer Res. 2006;66(16):7849-53. 
100 
 
56. Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, et al. 
Human X-box binding protein-1 confers both estrogen independence and antiestrogen 
resistance in breast cancer cell lines. The FASEB Journal. 2007;21(14):4013-27. 
57. Fang Y, Yan J, Ding L, Liu Y, Zhu J, Huang C, et al. XBP-1 increases ERα 
transcriptional activity through regulation of large-scale chromatin unfolding. Biochem 
Biophys Res Commun. 2004;323(1):269-74. 
58. Gu Z, Lee RY, Skaar TC, Bouker KB, Welch JN, Lu J, et al. Association of interferon 
regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element 
binding with acquired resistance to Faslodex (ICI 182,780). Cancer Res. 
2002;62(12):3428-37. 
59. Moretti L, Cha YI, Niermann KJ, Lu B. Switch between apoptosis and autophagy: 
radiation-induced endoplasmic reticulum stress? Cell cycle. 2007;6(7):793-8. 
60. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour 
development: friend or foe? Nat Rev Cancer. 2004;4(12):966-77. 
61. Okada T, Yoshida H, Akazawa R, Negishi M, Mori K. Distinct roles of activating 
transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like 
endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded 
protein response. Biochem J. 2002;366:585-94. 
62. Novoa I, Zeng H, Harding HP, Ron D. Feedback inhibition of the unfolded protein 
response by GADD34-mediated dephosphorylation of eIF2α. The Journal of cell biology. 
2001;153(5):1011-22. 
63. Zwang Y, Oren M, Yarden Y. Consistency test of the cell cycle: roles for p53 and 
EGR1. Cancer Res. 2012;72(5):1051-4. 
101 
 
64. Brown JR, Nigh E, Lee RJ, Ye H, Thompson MA, Saudou F, et al. Fos family members 
induce cell cycle entry by activating cyclin D1. Mol Cell Biol. 1998;18(9):5609-19. 
65. Schmitt JM, Wayman GA, Nozaki N, Soderling TR. Calcium activation of ERK 
mediated by calmodulin kinase I. J Biol Chem. 2004;279(23):24064-72. 
66. Agell N, Bachs O, Rocamora N, Villalonga P. Modulation of the Ras/Raf/MEK/ERK 
pathway by Ca 2+, and calmodulin. Cell Signal. 2002;14(8):649-54. 
67. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic 




















SRC COUPLES ESTROGEN RECEPTOR TO THE ANTICIPATORY UNFOLDED 
PROTEIN RESPONSE AND REGULATES CELL FATE UNDER STRESS 
 
ABSTRACT 
Accumulation of unfolded protein, or other forms of stress, activates the classical reactive 
unfolded protein response (UPR). Estrogen and other mitogenic hormones act through 
their receptors to rapidly elicit phosphorylation of phospholipase C γ (PLCγ), activating 
the PLCγ-mediated, tumor-protective, anti-apoptotic, anticipatory UPR. We show that the 
oncogene c-Src is a rate-limiting regulator whose tyrosine kinase activity couples 
estrogen and progesterone activation of their receptors to activation of the anticipatory 
UPR. Src-dependent, hormone-mediated activation of the protective anticipatory UPR 
protected cancer cells against subsequent UPR-mediated cell death. To probe the role of 
Src, we used the preclinical anticancer drug, BHPI, an estrogen receptor α (ERα) 
biomodulator that induces lethal hyperactivation of the anticipatory UPR, resulting in 
necrotic cancer cell death. After unbiased long-term selection for BHPI-resistant human 
breast cancer cells, 4/11 BHPI-resistant T47D clones and nearly all the MCF-7 clones 
exhibited reduced levels of normally growth-stimulating Src. Rapid, proteasome-
independent turnover and loss of Src contributes to resistance to otherwise lethal 
concentrations of BHPI. Supporting the conclusion that the BHPI-resistant Src-deficient 
cells are defective in an early step in the anticipatory UPR, while BHPI failed to induce 
the UPR marker spliced XBP-1 mRNA, induction of sp-XBP1 by the reactive UPR 
activators tunicamycin and thapsigargin was unaffected. Moreover, Src overexpression 
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by virus transduction restored sensitivity to BHPI. Furthermore, in wild type cells, several-
fold knockdown of Src, but not of ERα, strongly blocked BHPI-mediated UPR activation 
and subsequent HMGB1 release and necrotic cell death. Supporting Src linking estrogen 
and progesterone to activation of the anticipatory UPR, we identified extranuclear 
complexes of ERα:Src:PLCγ and progesterone receptor:Src:PLCγ. Thus, Src plays a 
previously undescribed pivotal role in activation of the tumor protective anticipatory UPR, 
thereby increasing the resilience of breast cancer cells. This is a new role for Src and the 
UPR in breast cancer. 
 
INTRODUCTION 
The endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR), 
plays a central role in the maintenance of protein folding quality control and homeostasis. 
In the well-studied reactive UPR, cancer cells respond to unfolded or misfolded proteins, 
hypoxia, nutritional deprivation and therapy-induced stress by activating the three arms 
of the UPR, PERK, IRE1α and ATF6α, reducing protein production and increasing protein 
folding capacity (1). Building on initial work in B cells (2), we, and others, described a 
protective anticipatory UPR pathway in which the mitogenic hormones, estrogen (E2), 
epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) act through 
their respective receptors to pre-activate the UPR and anticipate future needs for 
increased protein folding capacity required to support hormone-stimulated cell 
proliferation (3-7). Notably, mild and transient E2 and EGF activation of the anticipatory 
UPR elicits an adaptive response that protects cancer cells against subsequent UPR-
mediated apoptosis (3, 4). Moreover, analysis of data from ~1,000 breast cancer patients 
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showed that estrogen (17-estradiol, E2)-estrogen receptor (ERα)-related activation of a 
UPR gene index at diagnosis was tightly correlated with subsequent tamoxifen resistance, 
tumor recurrence and a poor prognosis. While a role for ERα in activation of the 
anticipatory UPR was clearly established, the key rate-limiting regulator that couples E2-
ERα to tyrosine phosphorylation and activation of phospholipase C γ (PLCγ), initiating the 
anticipatory UPR pathway (Figure 1) was unknown (3, 4, 6). We demonstrate that the 
well-studied oncogene cellular Src (c-Src) is the activated rate-limiting tyrosine kinase 
that couples estrogen:ERα and progesterone:PR to activation of the anticipatory UPR. 
The proto-oncogene c-Src is a non-receptor tyrosine kinase with critical roles in 
signaling pathways involved in cancer cell proliferation, survival, angiogenesis and 
metastasis (8-10). Although Src has been known to interact with ERα and PR (11-14), a 
role for Src in coupling ERα and PR action to the UPR had not been reported. 
While moderate and transient activation of the reactive and anticipatory UPR pathways 
serves an adaptive function that promotes cancer progression and therapy resistance; 
severe unresolvable EnR stress elicits strong and sustained activation of the reactive 
UPR, activating multiple pro-apoptotic pathways (15-17). In contrast, we recently showed 
that strong and sustained activation of the anticipatory UPR results in ATP depletion and 
necrotic cell death (Figure 1) (18). We targeted the anticipatory UPR pathway with the 
promising preclinical breast cancer drug, BHPI, which acts through ERα to induce lethal 
anticipatory UPR hyperactivation (18-21). We explored the role of Src in both protective 
and cytotoxic anticipatory UPR activation. Our studies describe a previously unexplored, 
often rate-limiting role for Src in coupling steroid receptor action to life-death decisions 




MATERIALS AND METHODS 
Cell Culture and Reagents 
    T47D and MCF-7 cells were from ATCC. MCF7-ERαHA cells were provided by E. 
Alarid. T47D-ERαY537S (TYS) cells were made as described(20).  BHPI resistant clones 
were derived from T47D cells. Cells were grown in the following conditions: T47D (MEM, 
10% FBS), MCF-7 (MEM, 5% FBS), MCF7-ERαHA (DMEM, 10% FBS), TYS (MEM, 10% 
CD-FBS), BHPI-resistant clones (MEM, 10% FBS + 1 μM BHPI for T47D clones; MEM, 
5% FBS + 5 μM BHPI for MCF-7 clones). Reagents used were: Dasatinib, Saracatinib, 
MG132 (Selleck Chemicals, TX), Tunicamycin (Sigma-Aldrich, MO), 35S-methionine 
(Perkin Elmer, MA). 
Western Blotting 
    Western blotting was carried out as previously described(22). The following primary 
antibodies were used: p-PLCγ (Cell Signaling Technology (CST) #14008), PLCγ (CST 
#5690), p-Src (CST #6943), Src (CST #2110), PR (CST #3153), BiP (CST #3177), p-ERK 
(CST #4370), ERK (CST #4695), p-eIF2α (CST #3398), eIF2α (CST #5324), p-PERK 
(CST #3179), PERK (CST #5683),ERα (Santa Cruz, sc-8002), HMGB1 (Abnova, 
H00003146-M08), β-actin (Sigma, A1978). Antibodies were proved with HRP-conjugated 
secondary antibodies (ThermoFisher, MA) and imaged with the ECL2 detection kit 
(ThermoFisher) using a PhosphorImager (GE Healthcare, IL). 
Co-immunoprecipitation 
    Cells were lysed with non-denaturing lysis buffer (20 mM Tris HCl, pH 8; 137 mM NaCl; 
1% NP-40; 2 mM EDTA) with proteinase inhibitor cocktail. Whole cell lysates obtained by 
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centrifugation were incubated with 1 μg of ERα (Santa Cruz, sc-543) or PR (Santa Cruz, 
sc-7208) antibody crosslinked protein A Dynabeads (ThermoFisher) overnight at 4°C. 
The immunocomplexes were then washed with washing buffer (10mM Tris, pH 7.4; 1mM 
EDTA; 1mM EGTA, pH 8.0; 150mM NaCl; 1% Triton X-100; 0.2mM sodium 
orthovanadate; protease inhibitor cocktail) three times and separated for immunoblotting 
analysis. 
siRNA Knockdown 
    siRNA knockdowns were performed using DharmaFECT1 and 100 nM ON-TARGET 
plus non-targeting pool or SMARTpools for ERα, PLCγ and Src (Dharmacon, CO). 
Transfection conditions were as described(22). 
Real-time PCR 
    300 000 cells were plated and cultured as described(22). Total RNA of three biological 
replicates was collected using a Qiagen RNAeasy kit and cDNA libraries were prepared 
using a ProtoScript® First Strand cDNA Synthesis Kit (NEB, MA).  
Cell Proliferation Assay 
    Indicated number of cells were plated into 96-well plates. The next day, medium was 
changed to indicated treatment. The treatment medium was changed after 48 hr and cell 
numbers were measured with MTS reagent (Promega, WI) after 96 hr (72 hr for siRNA 
KD experiments) with indicated treatments. 
ATP Measurement 
    ATP depletion assay was performed as previously described(18) and ATP levels were 
measured using ATPlite Luminescence Assay System (Perkin Elmer, MA). 
Luminescence was measured using a PHERAStar plate reader (BMG Labtech, Germany). 
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Cell Viability Assay 
    300 000 Cells were cultured and plated as previously described(18). Cell viability and 
cell volume after indicated treatment were measured using a Countess II cell counter 
(ThermoFisher). 
Protein Synthesis Assay 
    Protein synthesis was analyzed by measuring incorporation of 35S-methionine into 
newly synthesized proteins. Cells were incubated with indicated treatments and 3 μCi 
35S-methionine (Perkin Elmer) was added for the last 30 min. of treatment. Cells were 
washed, lysed and clarified by centrifugation. Supernatants were spotted onto Whatman 
540 filter paper discs (Fisher Scientific, PA) and subsequently washed by 10% 
trichloroacetic acid (TCA) and 5% TCA. Trapped protein was solubilized, and filters were 
measured in a scintillation counter. 
Lentivirus Production 
    Src cDNA was amplified and inserted into a pCDH-CMV-MCS-EF1-PURO vector using 
an In-Fusion HD cloning kit (Clontech, CA). Lentivirus was produced by cotransfecting 
pCDH-Src or pHIV-Luciferase vector (Addgene #21375) with packaging vectors pCI-
VSVG (Addgene #1733) and psPAX2 (Addgene #12260) into HEK293 cells using 
Lipofectamine 3000 (ThermoFisher). 
Statistical Analysis 
    RNAseq data of normal tissues and primary tumors were obtained from the TCGA 
Research Network. Samples were grouped by hormone receptors status determined by 
IHC. Pearson correlation test was used to determine gene expression correlation 
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coefficients. Two-tailed Student’s t-test was used for comparisons between groups. One-




Steroid hormones activate phospholipase C γ through Src 
    Src is a major tyrosine kinase in cancer cells(9). Consistent with our earlier finding that 
UPR markers are elevated in ERα+ mammary carcinoma(3), compared to normal 
mammary gland tissue, Src expression is significantly elevated in ERα+ and in PR+ 
mammary carcinomas (Figure 2a). To explore whether Src mediates estrogen-ERα 
activation of PLCγ, we evaluated the effect of Src inhibition or knockdown on estrogen-
ERα stimulation of PLCγ phosphorylation. In ERα+ T47D and MCF-7 human breast 
cancer cells E2 increased phosphorylation and activation of Src and PLCγ with a 
maximum at 20 min. The Src inhibitor, dasatinib (Das), abolished phosphorylation and 
activation of Src and PLCγ (Figure 2b and 3a). PR interacts with Src through its proline-
rich domain (14), suggesting progesterone (P4) might also activate PLCγ and the 
anticipatory UPR through Src. P4 treatment stimulated Src and PLCγ phosphorylation in 
T47D cells and in TYS cells which express the ERαY537S mutation that is associated 
with reduced survival in metastatic breast cancer (20, 22). Dasatinib pretreatment blocked 
the P4-mediated increase in Src and PLCγ phosphorylation (Figure 2c and 3b). Notably, 
Src knockdown blocked E2- and P4-stimulated PLCγ phosphorylation (Figure 2d). Since 
a second set of Src siRNAs also blocked PLCγ phosphorylation (Figure 3c), these effects 
are not due to off-target effects of the siRNA. 
109 
 
Identification of multiprotein complexes containing ERα, Src and PLCγ and PR, Src 
and PLCγ 
    Rapid PLCγ phosphorylation stimulated by E2 and P4 suggested direct interactions 
between ERα, Src and PLCγ and PR, Src and PLCγ. Using co-immunoprecipitation (co-
IP), we tested for the existence of ERα:Src:PLCγ and PR:Src:PLCγ complexes. Since 
membrane ERα is only ~5% of the total cellular pool(23), MCF7-ERαHA cells were used 
to increase total ERα expression (19). Compared to control lysates immunoprecipitated 
using non-specific rabbit IgG, immunoprecipitation with ERα antibody resulted in an E2-
dependent increase in co-immunoprecipitated Src and PLCγ (Figure 2e). In TYS cells 
where PR expression is high(22), Src and PLCγ co-immunoprecipitated with anti-PR but 
not with control rabbit IgG (Figure 2f). Unlike the ERα-Src-PLCγ complex, association of 
PR, Src and PLCγ was not further enhanced by progesterone. These data indicate that 
acting by direct physical association in multiprotein complexes, E2-ERα and P4-PR 
activate Src kinase and Src phosphorylates and activates PLCγ, initiating the anticipatory 
UPR. 
Elevated Src expression enhances E2 and P4 activation of the anticipatory UPR and 
adaptation to drug-induced stress 
Since we showed that UPR activation at diagnosis is strongly correlated with a poor 
prognosis in breast cancer(3), and Src both couples ERα to anticipatory UPR activation 
and is overexpressed in mammary carcinomas, we explored whether Src overexpression 
correlated with overexpression of the oncogenic UPR-induced chaperone 
HSPA5/BiP/GRP78 (24).  In vivo data from The Cancer Genome Atlas (TCGA) 
demonstrated that in ERα+ and PR+ mammary carcinomas in which Src was also 
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upregulated, there was up-regulation of UPR marker genes, especially the IRE1α 
pathway targets XBP1 and HSPA5 (Figure 4a). Thus, Src-mediated PLCγ activation may 
be responsible for anticipatory UPR activation in these ERα and PR positive breast 
cancers. To test our hypothesis, we monitored levels of the UPR activation marker, 
spliced XBP1 mRNA (sp-XBP1). Both E2 and P4 increased sp-XBP1 in breast cancer cells. 
Inhibiting Src with dasatinib or saracatinib significantly reduced sp-XBP1 mRNA levels 
(Figure 4b,c and 5a,b). sp-XBP1 is a transcription factor and induces BiP and other EnR 
chaperones (25). Consistent with their induction of sp-XBP1 mRNA, E2 and P4 elevated 
BiP expression in T47D cells and Src knockdown blocked BiP induction (Figure 4d). 
Estrogen pretreatment elicits chaperone induction and renders cells resistant to exposure 
to lethal concentrations of tunicamycin (TUN) (3). In contrast to estrogen, which increases 
cell proliferation, complicating analysis, progesterone did not activate the pro-proliferation 
ERK pathway (Figure 4e), or increase cell number (Figure 5c,d).  Notably, pretreating 
cells with P4 elicited 4-fold and 2-fold increases in the concentration of TUN required to 
induce apoptosis in T47D and TYS cells, respectively; blocking UPR activation with 
dasatinib re-sensitized cells to TUN (Figure 4f,g). Thus, Src-mediated anticipatory 
activation of the UPR, resulting in increased chaperone production, and protects tumor 
cells against apoptotic cell death induced by prolonged EnR stresses. 
Src is required for strong and sustained activation of the UPR 
    BHPI, acting through ERα, elicits strong and sustained activation of the anticipatory 
UPR (18, 19). Opening of IP3R calcium channels induces sustained Ca2+ release from 
the EnR. To restore Ca2+ homeostasis, sarco/endoplasmic reticulum Ca2+-ATPase 
(SERCA) pumps use ATP to pump Ca2+ back into the EnR lumen (19), creating a futile 
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cycle of pumping and release that depletes intracellular ATP. BHPI stimulated a ~40% 
decline in ATP levels, which was partially blocked by Src knockdown (Figure 6a). We next 
explored whether Src was critical for strong UPR activation. BHPI robustly induced sp-
XBP1 mRNA and dasatinib largely blocked sp-XBP1 induction (Figure 6b). BHPI strongly 
stimulates the PERK arm of the UPR leading to protein synthesis inhibition(19). 
Pretreatment with dasatinib blocked BHPI-induced PERK activation reducing 
downstream phosphorylation of eIF2α (Figure 7a,b).  
    Sustained UPR activation induced by BHPI results in classical necrosis phenotypes, 
including plasma membrane disruption and leakage of intracellular contents(18).  We 
assessed loss of membrane integrity by monitoring leakage into the medium of the widely 
used marker, high mobility group box 1 (HMGB1). 24h BHPI treatment increased HMGB1 
release and Src knockdown reduced HMGB1 leakage (Figure 6c).  To evaluate cell 
viability, we quantitated cell death using an automated trypan blue exclusion assay. In 
T47D, TYS and MCF-7 cells, ablating Src signaling by knockdown or with dasatinib, 
nearly abolished BHPI’s ability to induce cell death. Moreover, a longer three-day MTS 
assay confirmed that Src knockdown reversed BHPI inhibition of cell proliferation (Figure 
6d-f). Src knockdown only reduces Src protein ~3-fold (Figure 4c), suggesting Src, not 
ERα might be limiting for activation of the anticipatory UPR. To explore this, we evaluated 
the effect of ERα knockdown on BHPI inhibition of cell proliferation. Although the extent 
of ERα knockdown was at least as great as Src knockdown (Figures 4c and 7c), ERα 
knockdown did not block BHPI inhibition of cell proliferation (Figure 7d). These data 
suggest that Src, not ERα, is limiting in the complex that initiates activation of the 
anticipatory UPR.  
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In ER+ breast cancer cells Src downregulation confers resistance to BHPI  
To explore Src’s roles in the anticipatory UPR and in development of resistance to BHPI 
in tumor cells, we performed long-term selections for breast cancer cells resistant to 
growth inhibition by BHPI. Initially, BHPI treatment led to rapid death of nearly all cells. 
Over many weeks BHPI-resistant colonies grew out. We isolated T47D and MCF-7 
colonies that survived long-term selection in 1 μM (T47D) and 5 μM (MCF-7) BHPI. BHPI-
resistance could arise due to changes that diminish lethal BHPI hyperactivation of the 
anticipatory UPR, or from changes in growth or death pathways that counter UPR 
hyperactivation. We therefore compared the effect of the apoptosis inducer staurosporine 
(STS) as well as BHPI in T47D and MCF-7 cells and in BHPI-resistant T47D clone 1 (TB1) 
and MCF-7 clone 5 (MB5) cells. Flow cytometry showed that while both BHPI and STS 
induced cell death in the wild-type T47D and MCF-7 cells, only STS induced death of the 
BHPI-resistant TB1 and MB5 cells (Figure 8). 
Since the TB1 cells were not broadly resistant to cell death, we initially explored effects 
on proteins in the anticipatory UPR pathway and on UPR activation. Since long-term 
treatment with aromatase inhibitors selects for tumors that contain constitutively active 
ERα mutations and BHPI acts through ERα, it seemed possible we would identify 
mutations in ERα with diminished interaction with BHPI. Interestingly, sequencing of all 
11 BHPI-resistant T47D clones showed there were no mutations in ERα. Since BHPI acts 
through the ERα-Src-PLCγ complex to hyperactivate the anticipatory UPR pathway, we 
explored the levels of these proteins in the BHPI-resistant clones. Consistent with a rate-
limiting role for Src in the anticipatory UPR, 4 of 11 T47D clones (clone 1, 3, 4 and 11) 
and 7 of 8 MCF-7 clones showed reduced Src expression (Figure 9a and 10a). Several 
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BHPI-resistant clones displayed reduced levels of ERα. We further characterized T47D 
clones: TB1 (moderately reduced Src, ERα and PLCγ), TB3 (reduced Src) and TB11 
(reduced ERα, PLCγ and slightly reduced Src) and MCF-7 clone MB5 (reduced Src and 
ERα) and MB7 (reduced Src and ERα). T47D clone TB8 (Src not reduced) was a control.  
TB1, TB3 and TB11 exhibited reduced sensitivity to estrogen and showed slow growth in 
BHPI (Figure 10b,c). In contrast, TB8 lost E2 stimulation of cell proliferation, while BHPI 
slightly increased its proliferation (Figure 10b,c). This suggests TB8 cells with normal Src 
levels exhibit a different BHPI resistance mechanism than cells with reduced levels of Src. 
Compared to parental MCF-7 cells, MB5 and MB7 cells showed slightly reduced E2-
stimulated cell proliferation and 1 μM BHPI had minimal effects on their proliferation 
(Figure 9b,c). Since T47D and MCF-7 cells display different sensitivity to growth inhibition 
and killing by BHPI (Figure 9c and 10c), data obtained from the two sets of BHPI-resistant 
cell lines should be broadly applicable. 
    We then compared UPR activation in parental cells and BHPI resistant clones. BHPI-
resistant T47D and MCF-7 clones exhibited minimal BHPI induction of sp-XBP1 (Figure 
11a and 9d). To test whether reactive UPR responses were impaired in the resistant 
clones, we compared sp-XBP1 expression in parental cells and in resistant clones treated 
with the classic UPR activators TUN and thapsigargin (THG). Consistent with an intact 
reactive UPR pathway in the BHPI resistant clones, sp-XBP1 mRNA induction by the 
UPR activators was nearly identical in parental and BHPI-resistant clones (Figure 11b 
and 9e). In 100 nM BHPI, which blocks growth and kills wild type T47D cells (Figure 10a), 
activation of the PERK-p-eIF2α arm of the UPR and inhibition of protein synthesis were 
nearly abolished in the resistant clones (Figure 11c,d). While increasing BHPI to 1 μM 
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restored strong BHPI inhibition of protein synthesis, these cells still grow slowly (Figures 
10c and 11d). Notably, while 100 nM and 1 μM BHPI strongly reduced ATP levels in wild-
type T47D and MCF-7 cells, in the BHPI-resistant clones, BHPI lost the ability to reduce 
ATP levels (Figure 9f and 11e) and therefore failed to induce necrotic cell death (Figure 
5f) and HMGB1 release (Figure 11g). Since BHPI resistance arose from impaired 
activation of the anticipatory UPR pathway, and Src, which triggers activation of the 
pathway, was reduced in several of the clones, we explored whether restoring Src levels 
could re-sensitize resistant clones to BHPI. 
Overexpressing Src re-sensitizes resistant breast cancer cells to BHPI-stimulated 
UPR hyperactivation  
    To test whether down-regulation of Src was critical for acquisition of BHPI resistance 
and was rate-limiting for UPR hyperactivation, we used transduction with a Src lentivirus 
and a control luciferase lentivirus. Although the Src lentivirus increased Src levels in T47D 
cells, it did not alter levels of the other components of the complex, ERα and PLCγ (Figure 
12a). Consistent with a saturating and rate-limiting level of Src in wild type T47D cells, 
increasing Src levels did not increase BHPI-induced cell death, while several-fold Src 
knockdown reduced cell death. Moreover, the higher Src level in T47D cells transduced 
with Src lentivirus greatly attenuated the effect of Src knockdown on BHPI-induced cell 
death (Figure 13a). Restoration of Src in BHPI-resistant cells was complicated by the 
surprising finding that BHPI treatment elicited rapid turnover of Src protein in the BHPI-
resistant clones, but not in parental T47D cells. 100 nM BHPI for 1 hour did not reduce 
Src levels in T47D cells or in the TB8 clone (WT Src level), but reduced Src levels in TB1, 
TB3 and TB11 cells (Figure 12b). Moreover, 1-hour treatment with 1 μM BHPI, but not 
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100 nM BHPI, significantly reduced Src expression in MB5 cells. Surprisingly, Src 
depletion was not blocked by the proteasome-inhibitor MG132 (Figure 12c,d). Thus, viral 
transduction may only partially restore Src levels and function in the BHPI-resistant clones. 
While restoration of Src protein in BHPI-resistant TB1 cells did not significantly increase 
ATP depletion (Figure 12e), it increased phosphorylation of eIF2α, partially restored BHPI 
inhibition of protein synthesis and partially restored BHPI inhibition of cell proliferation 
(Figure 13b-d). These data show restoring the level of Src oncogene in BHPI-resistant 
cancer cells partially re-sensitizes the cells to BHPI-mediated UPR hyperactivation and 
cell death. 
    Consistent with our observations in T47D cells, 1 μM BHPI nearly eliminated 
expression of Src protein in MCF-7-derived MB5 cells and viral transduction partially 
restored Src expression (Figure 13e). Restoring Src expression in MB5 cells increased 
BHPI-mediated ATP depletion and inhibition of protein synthesis (Figure 13f,g). Notably, 
while 1 μM BHPI did not inhibit proliferation in MB5 cells transduced with control luciferase 
virus, it significantly inhibited cell proliferation in cells transduced with Src virus (Figure 
13h). These data show restoring the level of Src oncogene in BHPI-resistant cells re-
sensitizes them to BHPI-mediated UPR hyperactivation and cell death. 
 
DISCUSSION 
    How signals from hormones and biomodulators bound to steroid receptors elicit 
phosphorylation of PLCγ and activation of the anticipatory UPR was unknown. We show 
that a single activating kinase, Src, triggers both types of anticipatory UPR activation: the 
mild and transient tumor protective mode and the strong and sustained cancer-targeting 
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lethal mode (Figure 1). Although Src is abundant in ERα+ breast cancer cells, and was 
known to activate multiple pro-growth signaling pathways (26, 27), its key role in activation 
of the hormone-mediated anticipatory UPR unveils a previously unexplored oncogenic 
mechanism. Src’s role in rapid activation of the anticipatory UPR in cancer cells plays an 
enabling role in facilitating the diverse mitogenic activities of Src. In ERα+ breast cancer 
cells, acting through the anticipatory UPR, Src level and activity serve as a molecular 
rheostat integrating diverse signals. Activation of the UPR at diagnosis is strongly 
correlated with tumor recurrence, tamoxifen resistance and a poor prognosis (3). 
Consistent with our finding that constitutively active ERα mutations that are partially 
tamoxifen resistant elicit weak long-term activation of the anticipatory UPR (20, 22), in 
tamoxifen resistant MCF-7 cells, sustained and gradually increasing Src activation is 
observed (27).  
    While there have been several studies reported that Src activates PLCγ (28-30), in the 
absence of a downstream PLCγ activated pathway, these studies did not attract a great 
deal of interest. Our finding that Src is a rate-limiting controller of the anticipatory UPR 
provides a framework and context that integrates these seemingly diverse observations. 
For example, vitamin D receptor, in rat colonocytes stimulates PLCγ activation through 
Src-mediated tyrosine phosphorylation (29). Notably, the insect hormone ecdysone 
binding to ecdysone receptor (EcR) activated PLCγ in a Src-dependent manner and 
calcium in the cell increased (31, 32). This activity was shown to be essential for 
ecdysone-mediated insect development, but was not linked to the UPR. Our work makes 
it highly likely that ecdysone-EcR are acting through the Src-PLCγ pathway to provide an 
essential authorizing signal through activation of the anticipatory UPR. Conservation of 
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the Src-regulated anticipatory UPR from insects to humans demonstrates its importance. 
Similarly, the observation that unconjugated bile acids act through Src and result in death 
of esophageal cancer cells raises the possibility that bile acids, perhaps acting through 
bile acid receptors, are inducing lethal activation of the anticipatory UPR (33). In some 
systems, such as direct activation of Src and PLCγ by sphingolipids (34), Src activation 
may result from perturbation of its membrane environment and likely does not require an 
activating hormone receptor. 
    Usually resistance to an anticancer drug involves either mutation of its target, as is 
seen with aromatase inhibitors and ERα mutations in breast cancer (35, 36), or 
overexpression of the target protein as is seen with antiandrogens and androgen receptor 
(AR) in prostate cancer (37). Unexpectedly we found that clonal cell lines identified in 
unbiased long-term selection for resistance to BHPI often exhibited down-regulation of 
pro-growth Src. Since UPR activation by classical UPR activators tunicamycin and 
thapsigargin was unaffected, it is likely that down-regulation of Src was the key event in 
acquisition of BHPI resistance. Notably, down-regulation of Src was more common than 
down-regulation of ERα, the direct target of BHPI. Moreover, Src overexpression re-
sensitized resistant clones to BHPI-stimulated UPR hyperactivation. 
    In normal cells, activated Src undergoes reversible protein dephosphorylation and 
ubiquitin-mediated protein degradation (38, 39). Therapeutic HSP90 inhibitors enhance 
Src degradation in cancer cells (40, 41). Consistent with a regulatory role for degradation 
controlling Src level and ultimately activity, in several BHPI-resistant breast cancer cell 




    Our findings that moderate down-regulation of Src leads to BHPI resistance in long-
term culture and that 3-4 fold knockdown of Src is sufficient to strongly inhibit BHPI-
induced cell death are surprising in light of the overexpression and abundance of Src in 
ERα+ breast cancer cells. Only a small fraction of ERα is extranuclear near the plasma 
membrane, and much of the extranuclear ERα is devoted to activating ERK and other 
signaling pathways. Therefore, total Src is in large excess over what is required to 
complex with ERα and PLCγ and activate the anticipatory UPR. Partitioning of limiting 
Src between the ERα- and PLCγ-regulated anticipatory UPR and other signal 
transduction pathways likely provides a novel mechanism for coordinating activity of the 
UPR and the growth-stimulating signaling pathways. While this type of limiting availability 
due to competition between different complexes is well studied in the context of 
transcription factors, such as CBP (42), it has been less widely considered in the control 
of UPR activation.  
    Taken together our findings that Src is down-regulated in BHPI-resistant clones, that 
3-4 fold down-regulation of Src attenuates both the protective activation of the anticipatory 
UPR, and BHPI-induced lethal hyperactivation of the anticipatory UPR, strongly suggests 
elevated levels and activity of Src in breast cancer play a major role in key life-death 
















Figure 4.2 Src mediates steroid hormone-stimulated PLCγ phosphorylation. (a) Src 
gene expression in normal tissues (NT), ERα+ primary breast cancer (ER+ TP) and PR+ 
primary breast cancer (PR+ TP). * indicates a significant difference among groups using 
one-way ANOVA followed by Tukey’s post hoc test. *** P < 0.001. (b,c) Western blotting 
analysis of phosphorylated PLCγ (p-PLCγ, tyrosine 783), total PLCγ, phosphorylated Src 
(p-Src), total Src and β-actin in ERα+ T47D cells treated with vehicle control or dasatinib 
(Das) for 5 min., followed by treatment with 10 nM E2 (b) or 10 nM progesterone (P4) (c). 
(d) Western blotting analysis of Src, p-PLCγ, PLCγ and β-actin protein levels following 
treatment of T47D cells with either 100 nM non-coding (NC) or Src siRNA SMARTpool, 
followed by treatment with vehicle, E2 or P4 for 30 min. (e) Co-immunoprecipitation and 
western blotting analysis of ERα, Src and PLCγ interactions in MCF7-ERαHA cells. Using 
magnetic beads, cell lysates were immunoprecipitated with ERα or mouse IgG antibodies. 
The immunoprecipitates were blotted with PLCγ, Src and ERα antibodies. (f) Co-
immunoprecipitation and western blot analyses of PR, Src and PLCγ interactions in T47D-
ERαY537S (TYS) cells. Cell lysates were immunoprecipitated with PR or mouse IgG 












Figure 4.3 Src mediates steroid hormones-stimulated PLCγ phosphorylation. (a) 
Western blot analysis of phosphorylated PLCγ (p-PLCγ, tyrosine 783), total PLCγ, 
phosphorylated Src (p-Src), total Src and β-actin in ER+ MCF-7 cells treated with a vehicle 
control or dasatinib (Das) for 5 min, followed by treatment with 10 nM E2 for the indicated 
time. (b) Western blot analysis of p-PLCγ, total PLCγ, p-Src, total Src and β-actin in TYS 
(T47D-ERαY537S) cells treated with vehicle or dasatinib for 5 min, followed by treatment 
with 10nM progesterone (P4) for the indicated time. (c) Western blot analysis of Src, p-
PLCγ, PLCγ and β-actin protein levels following treatment of T47D cells with either 100 
nM non-coding (NC) or Src siRNA SMARTpool (version 2), followed by treatment with 





Figure 4.4 Estrogen and progesterone activate the protective anticipatory unfolded 
protein response through Src.  (a) UPR marker gene expression in normal breast 
tissues (NT), ERα positive primary breast cancer (ER+ TP) and PR positive primary 
breast cancer (PR+ TP). * indicates a significant difference among groups using one-way 
ANOVA followed by Tukey’s post hoc test. * P < 0.05, *** P < 0.001. (b,c) qRT-PCR 
analysis of spliced XBP1 (sp-XBP1) mRNA level in T47D cells treated for 15 min. with 
vehicle, or with 200 nM dasatinib, followed by treatment with vehicle, 10 nM E2 (b) or P4 
(c) for 4 hr. Different letters indicate a significant difference among groups (P<0.05) using 
one-way ANOVA followed by Tukey’s post hoc test (mean ± s.e.m., n = 3). (d) Western 
blotting analysis of BiP and β-actin protein levels following treatment of T47D cells with 
either 100 nM non-coding (NC) or Src siRNA SMARTpool, followed by treatment with 
vehicle, E2 or P4 for 4 hr. (e) Western blot analysis of PR, phosphorylated ERK (p-ERK), 
total ERK and β-actin protein levels in T47D cells and TYS cells treated with vehicle, 10 
nM E2 or 10 nM P4 for 24 hr. (f,g) Weak dasatinib-sensitive anticipatory activation of UPR 
with progesterone protects cells against subsequent tunicamycin-induced cell death. 
T47D (f) and TYS (g) cells were maintained in medium with ethanol-vehicle (Untreated), 
10 nM P4 or P4 plus 200 nM dasatinib for 48 hr. Vehicle control, P4 and dasatinib were 
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Figure 4.4 (cont.) removed from medium and cells were then treated with the indicated 
concentrations of tunicamycin (TUN) for 96 hr. Different letters indicate a significant 
difference among groups (P<0.05) using one-way ANOVA followed by Tukey’s post hoc 














Figure 4.5 Steroid hormones activate anticipatory UPR through Src. (a,b) qRT-PCR 
analysis of spliced XBP1 (sp-XBP1) gene expression in T47D cells treated with vehicle 
or 100 nM saracatinib for 15 min, followed by treatment with vehicle, 10 nM E2 (a) or P4 
(b) for 4 hr. Different letters indicate a significant difference among groups (P<0.05) using 
one-way ANOVA followed by Tukey’s post hoc test (mean ± s.e.m., n = 3). (c,d) MTS 
assay of T47D (c) and TYS cells (d) treated with vehicle, 10 nM P4, 200 nM dasatinib 
(Das) and P4 + Das for 96 hr. (d) Different letters indicate a significant difference among 
groups (P < 0.05) using one-way ANOVA followed by Tukey’s post hoc test (mean ± 





Figure 4.6 BHPI kills ERα positive breast cancer cells by hyperactivating the UPR 
through Src. (a) Src knockdown blocks cytotoxic BHPI-mediated ATP depletion. ATP 
level analysis following treatment of T47D cells with either 100 nM NC siRNA or Src 
siRNA SMARTpool, followed by treatment for 24 hr. with vehicle or the indicated 
concentration of BHPI. * indicates a significant difference among groups using Student’s 
t-test. * P< 0.05, ** P < 0.005 (mean ± s.e.m., n = 6). (b) qRT-PCR analysis of sp-XBP1 
gene expression in T47D, TYS and MCF-7 cells treated with vehicle or 200 nM dasatinib 
for 15 min., followed by treatment with vehicle or 100 nM BHPI. Different letters indicate 
a significant difference among groups (P<0.05) using one-way ANOVA followed by 
Tukey’s post hoc test (mean ± s.e.m., n = 3). (c) Western blot analysis of BHPI-stimulated 
HMGB1 release into the cell culture medium at 50 or 100 nM BHPI following treatment of 
T47D cells with either 100 nM NC or Src siRNA SMARTpool. (d) Src knockdown blocks 
BHPI-induced cell death. T47D and TYS cells were treated with 100 nM NC or Src siRNA 
followed by treatment with 100 nM BHPI for 24 (T47D) or 1 hr (TYS). (e)  Inhibiting Src 
activity blocks BHPI-induced cell death. MCF-7 cells were treated with 2 hr. treatment 
with vehicle, 100 nM BHPI, 200 nM dasatinib or dasatinib + BHPI. (d,e) Cell death was 
monitored by an automated trypan blue assay. Different letters indicate a significant 
difference among groups (P<0.05) using one-way ANOVA followed by Tukey’s post hoc 
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Figure 4.6 (cont.) test (mean ± s.e.m., n = 3). (f) MTS assay following treatment of T47D 
cells with either 100 nM NC or Src siRNA SMARTpool, followed by treatment with vehicle 
or indicated concentration of BHPI for 72 hr. * indicates a significant difference among 













Figure 4.7 BHPI hyperactivates UPR through Src kinase. (a) Western blot of p-Src, 
total Src, phosphorylated PERK (p-PERK), total PERK, phosphorylated eIF2α (p-eIF2α), 
total eIF2α and β-actin in T47D cells treated with a vehicle control or dasatinib for 5 min, 
followed by treatment with 100nM BHPI for the indicated time. (b) Western blot of p-PERK, 
total PERK and β-actin in TYS cells treated with a vehicle control or dasatinib for 5 min, 
followed by treatment with 10 nM P4 or 100nM BHPI for 20 min. (c) Western blot of ERα, 
Src, PLCγ and β-actin following treatment of T47D cells with either 100 nM NC or ERα 
siRNA SMARTpool. (d) MTS assay following treatment of T47D cells with either 100 nM 
NC or ERα siRNA SMARTpool, followed by treatment with vehicle or the indicated 




Figure 4.8 BHPI resistant cells remain sensitive to an apoptosis inducer. (a) Flow 
cytometry histograms of annexin V-FITC (FITC-A) and propidium iodide (PI) staining of 
T47D and TB1 cells after treatment with 1 μM staurosporine (STS) or 1 μM BHPI for 12 
hr. (b) Flow cytometry histograms of annexin V-FITC and PI staining of MCF-7 and MB5 




Figure 4.9 Identification and characterization of the BHPI-resistant MCF-7 clones. 
(a) Western blot analysis of PLCγ, ERα, Src and β-actin in MCF-7 parental cells and BHPI 
resistant clones treated with vehicle or 5 μM BHPI. All BHPI resistant clones were cultured 
in medium containing 5 μM BHPI. (b,c) Proliferation of MCF-7 and resistant clones treated 
with vehicle, 10 nM E2 (b) and 1 μM BHPI (c) for 96 hr. Different letters indicate a 
significant difference among groups (P<0.05) using one-way ANOVA followed by Tukey’s 
post hoc test (mean ± s.e.m., n = 6). (d, e) qRT-PCR analysis of sp-XBP1 gene 
expression in MCF-7 and BHPI resistant clone MB5 treated for with either vehicle, or 1 
μM BHPI for 4 hr (d), or 10 μg/ml tunicamycin (TUN) or 1 μM thapsigargin (THG) for 2 hr 
(e). * indicates a significant difference among groups using one-way ANOVA followed by 
Tukey’s post hoc test. *** P < 0.001 (mean ± s.e.m., n = 3). (f) ATP levels in MCF-7 and 
BHPI-resistant clones treated with vehicle or indicated concentrations of BHPI for 24 hr. 
* indicates a significant difference among groups using Student’s t-test. *** P < 0.001 




Figure 4.10 Identification and characterization of the BHPI-resistant clones. (a) 
Western blot of PLCγ, ERα, Src, phosphorylated eIF2α (p-eIF2α), eIF2α and β-actin in 
T47D parental cells and BHPI resistant clones treated with vehicle or 1 μM BHPI. All BHPI 
resistant clones were cultured in medium containing 1 μM BHPI. (b) Proliferation of T47D 
and resistant clones treated with vehicle, 10 nM E2 and indicated concentrations of BHPI 
(c) for 96 hr. (b,c) Different letters indicate a significant difference among groups (P < 





Figure 4.11 Src downregulation confers BHPI resistance on breast cancer cells. (a, 
b) qRT-PCR analysis of sp-XBP1 gene expression in wild type T47D and in BHPI-
resistant clones treated with vehicle or 100 nM BHPI for 4 hr (a), 10 μg/ml tunicamycin 
(TUN) or 1 μM thapsigargin (THG) for 2 hr (b). Different letters (a) or * (b) indicate a 
significant difference among groups (P < 0.05) using one-way ANOVA followed by 
Tukey’s post hoc test. *** P < 0.001 (mean ± s.e.m., n = 3).  (c) Western blot of p-eIF2α, 
total eIF2α and β-actin protein levels in T47D and BHPI-resistant clones treated with 
vehicle or 100 nM BHPI for 1 hr. (d) Protein synthesis assay in T47D and BHPI-resistant 
clones treated with vehicle, 100 nM BHPI and 1 μM BHPI for 1 hr (mean ± s.e.m., n=4). 
(e) ATP levels in T47D cells and BHPI-resistant clones treated with vehicle or the 
indicated concentrations of BHPI for 24 hr. * indicates a significant difference among 
groups using Student’s t-test. * P< 0.05, *** P < 0.001 (mean ± s.e.m., n = 6). (f) Trypan 
blue exclusion assay for cell death in T47D and BHPI-resistant clones after 24 hr. 
treatment with vehicle, 100 nM BHPI or 1 μM BHPI. * indicates a significant difference 
among groups using one-way ANOVA followed by Tukey’s post hoc test. *** P < 0.001 
(mean ± s.e.m., n = 3). (g) Western blot showing HMGB1 release into the cell culture 





Figure 4.12 BHPI rapidly downregulates Src expression in BHPI resistant breast 
cancer cells. (a) Western blot of PLCγ and ERα of T47D cells transduced with luciferase-
expressing virus or Src-expressing virus following knockdown with either 100 nM NC or 
Src siRNA SMARTpool. All cells were treated with 100 nM BHPI for 24 hr. (b) Western 
blot analysis of Src and β-actin protein levels in T47D and BHPI resistant clones treated 
with vehicle or 100nM BHPI for 1 hr. (c) Western blot analysis of Src and β-actin protein 
levels in MB 5 treated with vehicle, 100 nM and 1 μM BHPI for 1 hr. (d) Western blot of 
Src and β-actin protein levels in MB5 cells treated with vehicle, 5 μM or 10 μM MG132 for 
15 min. followed treatment with vehicle or 1 μM BHPI for 1 hr. (e) ATP levels in TB1 cells 
treated with vehicle or 100 nM BHPI for 1 hr. following viral transduction with control virus 








Figure 4.13 Src overexpression partially restores sensitivity to BHPI in BHPI 
resistant cells. (a-h) For all virus transduction experiments, cells were cultured in 
medium containing virus for 24 hr., then kept in virus-free medium for 24 hr. to allow 
protein overexpression. (a) Western blot of Src and β-actin and trypan blue exclusion 
viability assay of T47D cells transduced with luciferase-expressing virus or Src-
expressing virus following knockdown with either 100 nM NC or Src siRNA SMARTpool. 
All cells were treated with 100 nM BHPI for 24 hours. Different letters indicate a significant 
difference among groups (P < 0.05) using one-way ANOVA followed by Tukey’s post hoc 
test (mean ± s.e.m., n = 3).  (b) Western blot of Src, p-eIF2α, total eIF2α and β-actin 
protein levels in TB1 cells treated with vehicle or 100 nM BHPI for 1 hr. following viral 
transduction with control virus or Src-expressing virus. (c) Protein synthesis in TB1 cells 
treated with vehicle or 100 nM BHPI for 1 hr. following viral transduction with control virus 
or Src-expressing virus (mean ± s.e.m., n = 4). (d) MTS assay of TB1 cells treated with 
vehicle or 100 nM BHPI for 96 hr. following viral transduction with control virus or Src-
expressing virus. (mean ± s.e.m., n = 6). (e) Western blot of Src and β-actin in MB5 cells 
treated with vehicle or 1 μM BHPI for 8 hr. following viral transduction with luciferase-
expressing virus or Src-expressing virus. (f) ATP level in MB5 cells treated with vehicle 
or 1 μM BHPI for 1 hr. following viral transduction with control virus or Src-expressing 
134 
 
Figure 4.13 (cont.) virus (mean ± s.e.m., n = 4). (g) Protein synthesis in MB5 cells treated 
with vehicle or 1 μM BHPI for 1 hr. following viral transduction with control virus or Src-
expressing virus (mean ± s.e.m., n = 4). (h) MTS assay of MB5 cells treated with vehicle 
or 1 μM BHPI for 72 hr. following viral transduction with control virus or Src-expressing 
virus (mean ± s.e.m., n = 6). (c,d,f,g,h) * indicates a significant difference among groups 










Figure 4.14 Graphic summary depicting correlation between Src level and 
anticipatory UPR activation. (a) Elevated Src expression in steroid hormone receptor 
positive (HR+) breast cancer cells facilitates E2- or P4-stimulated UPR activation and 
protects cells from accumulated UPR stress. (b) BHPI takes advantage of Src 
overexpression, hyperactivates the anticipatory UPR and tips the scale from protective to 
lethal. (c) In BHPI-resistant cells, reduced Src expression disrupts UPR activation, 
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Estrogen (E2), acting through estrogen receptor α (ERα), stimulates breast cancers 
proliferation and metastasis. Endocrine therapies using aromatase inhibitors, selective 
ER modulators (SERMs) and selective ER degraders (SERDs), inhibit E2:ERα activities, 
and are mainstays in treatment of ERα positive breast cancers (1). Even though these 
endocrine therapies are effective initially, selection and outgrowth of breast cancer cells 
resistant to endocrine therapy is common (2-4). The mechanisms underlying endocrine 
resistance are complex, however, with the advent of powerful DNA sequencing 
techniques, clustered mutations in the ERα LBD were identified in 20-40% of ERα positive 
metastatic breast cancers (3, 5-8). While all metastatic ERα positive breast cancers 
display resistance to endocrine therapy and ultimately to standard chemotherapy, 
patients with tumors harboring the common ERαY537S and ERαD538G mutations exhibit 
1-year and 6-month shorter median survival than patients whose metastatic tumors 
contain wild type ERα (9). To explore roles of these mutations, viral transduction，
CRISPR/Cas9 and long-term-estrogen-deprivation were used to express ERα LBD 
mutations in breast cancer cells (10-13). 
Studies on breast cancer cells bearing ESR1 mutations are limited and were either 
restricted to a single mutation (10), or lacked extensive functional analysis (13). We, using 
RNA sequencing, compared T47D cells harboring ERαY537S and ERαD538G mutations 
and parental cells at two time points and confirmed several key observations with the 
MCF-7 dataset. Surprisingly, multidimensional scaling (MDS) analysis show that the 
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mutations are not simply constitutively active ERα, and instead exhibit unique gene 
expression patterns. Moreover, we demonstrated that Y537S and D538G ESR1 
mutations are sufficient to confer on breast cancer cells partial resistance to antiestrogens 
and estrogen-independent cell proliferation. Compared to cells expressing ERαD538G, 
we and others, observe increased antiestrogen resistance in cell lines expressing 
ERαY537S (11, 13). 
Previous studies focused almost entirely on proliferation-related properties of ESR1 
mutations. However, ESR1 mutations were detected at higher allele frequency in 
metastases than in the primary breast cancers (8, 14). To probe the role of ESR1 
mutations in metastasis-related properties we improved the wildly used trans-well assay 
(15) which over simplified the complicated process of metastasis. To better quantify cell 
numbers, we replaced traditional crystal violet staining with luciferase-expressing 
lentivirus transduction, or luciferase gene transfection. Our modified invasion-
dissociation-rebinding (IDR) assay quantitates both the number of invaded cells and the 
number of invaded cells that then dissociate from the underside of the membrane and 
rebind on the bottom of the well. In the in vitro invasion-dissociation-rebinding assay, ERα 
mutations significantly increase both T47D cell invasion and dissociation-rebinding. 
Moreover, the dramatic increase in lung metastasis of TYS tumors compared to TDG 
tumors was not predicted by the conventional Matrigel and collagen invasion assays, but 
was better correlated with the dissociation-rebinding properties seen in the IDR assay. 
Our data shows that, compared to the traditional Matrigel invasion assay, our simple in 
vitro IDR assay explores cell properties that correlate with in vivo metastatic frequency 
and provides a useful in vitro model for investigation of metastasis-related properties. 
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To identify pathways contributing to these aggressive phenotypes of ERα mutant cells, 
we performed Gene Set Enrichment Analysis (GSEA) using T47D and MCF-7 RNAseq 
datasets. Using GSEA, we identified Myc target genes as one of the highly enriched 
pathway in ERα mutant cells; other upregulated pathways like “E2F targets” and “G2M 
checkpoint” are tightly correlated with Myc expression. Myc directly induces expression 
of cell cycle regulators, including Cyclin D, Cyclin E and E2Fs (16-18) and promotes cell 
cycle progression by regulating CDK phosphorylation and antagonizing cell cycle inhibitor 
expression (19, 20). Myc knockdown demonstrated that Myc is necessary for E2-
independent proliferation of the ERα mutant cells. Constitutive Myc expression in E2-
deprived parental cells was sufficient to induce moderate E2-independent proliferation. 
Myc overexpression in tumors has been correlated with cancer stemness, which leads to 
reduced responsiveness to anticancer drugs and increased metastatic potential (21, 22). 
In breast cancer cells, overexpression of Myc and its downstream targets Cyclin E1 and 
Cyclin D1 results in decreased sensitivity to antiestrogens (23, 24). An analysis of Myc in 
399 patients with ERα positive breast cancer showed that higher levels of Myc expression 
were associated with shorter relapse free survival (24). Notably, while these studies and 
our data demonstrate an important role for Myc in proliferation-related phenotypes and 
therapy resistance, Myc expression in T47D cells had no effect on metastasis-related 
invasion, dissociation and rebinding. 
In addition to Myc upregulation, the ERα mutant breast cancer cells exhibit alterations 
in protective pathways associated with resistance to cell death. The unfolded protein 
response (UPR) was upregulated in E2-treated T47D and MCF7 cells and in ERαY537S 
and ERαD538G mutants. UPR upregulation is consistent with our recent work 
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demonstrating E2-activation of the anticipatory UPR in ERα containing T47D and MCF-7 
breast cancer cells (25), in PEO4 ovarian cancer cells (26), and estrogen-independent 
UPR activation in TYS and TDG cells (12). This pathway is unlike conventional reactive 
UPR activation in which cells respond to stress by activating a protective moderate UPR 
pathway (27, 28). In our study, we describe a fundamentally different type of very rapid 
UPR activation that anticipates future needs and occurs in the absence of cell stress or 
accumulation of unfolded proteins. In less than 2 minutes, mitogenic hormones trigger 
PLC-mediated production of inositol triphosphate (IP3). IP3 binds to and opens the 
endoplasmic reticulum IP3R calcium channels releasing Ca2+ stored in the lumen of 
endoplasmic reticulum into the cytosol. This increase in cytosol Ca2+ stimulates activation 
of all three arms of the UPR. This anticipatory activation of the UPR is a newly identified 
pathway shared by several mitogenic hormones. We suggest this newly unveiled pathway 
is used by many, but not all, mitogenic hormones to prepare cells for the increased protein 
folding capacity that may company subsequent hormone-stimulated cell proliferation. 
Although this pathway is conserved from peptide hormones to steroid hormones, there 
are important differences in the activation mechanisms. VEGF induced UPR activation is 
not inhibited by blocking the ER calcium signal (29). However, EGF mediated activation 
of the UPR is totally dependent on IP3 mediated calcium release from the endoplasmic 
reticulum.  
Since a key feature of rapid anticipatory activation of the UPR is an increase in 
cytosolic calcium, we explored the effect of blocking calcium increase on well-
characterized actions of EGF-EGFR. The mitogenic action of EGF is mediated in part by 
regulation of immediate early gene expression. Two major EGF-induced immediate early 
146 
 
genes, c-fos and egr1 encode transcription factors important for cell cycle progression 
(30, 31). Rapid EGF:EGFR activation of the ERK signaling pathway is essential for 
induction of immediate early genes (32). Cytosolic calcium levels play an important role 
in regulating ERK activation (33, 34). However, blocking the transient and moderate 
increase in cytosol Ca2+ induced by EGF:EGFR activation had no effect on inhibiting 
EGF:EGFR stimulated ERK or AKT activation. Since blocking the EGF-induced increase 
in cytosol Ca2+ abolished induction and repression of gene expression by EGF, the 
anticipatory UPR pathway is not regulating immediate early gene expression through the 
ERK pathway. Transient calcium increase in the cytosol and ERK activation are two 
independent pathways regulated by EGF:EGFR that converge at the level of immediate 
early gene expression regulation.  
These results indicate that the EGF induced anticipatory UPR pathway facilitates 
EGF stimulated cell proliferation in at least two ways. First, it increases UPR chaperone 
production, which contributes to EGF stimulated cell proliferation. Second, it releases 
calcium from lumen of the endoplasmic reticulum and cooperates with the ERK signaling 
pathway to regulate immediate early gene expression.  
Previous studies suggested the G protein-coupled estrogen receptor, GPR30, could 
activate PLC and induce calcium mobilization (35). Our data showed that a GPR30 
agonist has no effect on the anticipatory UPR activation (25). The non-receptor tyrosine 
kinase, c-Src, on the other hand has been shown to associate with and activate PLCγ 
(36). Other members of the steroid receptor superfamily, vitamin D receptor, in rat 
colonocytes stimulates PLCγ activation through Src mediated tyrosine phosphorylation 
(37). In human breast tumors, c-Src expression is highly elevated compared to normal 
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breast epithelium and this overexpression leads to increased tyrosine kinase activity (38). 
These data suggest Src may play a critical role in steroid hormones induced PLCγ 
activation. In this study, we showed that estrogen and progesterone rapidly induced Src 
phosphorylation, which then activated PLCγ in breast cancer cells. 
Only approximately 5% of the total ERα protein population localizes at the membrane 
and can interact with other membrane proteins (39). Although less well characterized, 
progesterone receptor (PR) was known to translocate to the plasma membrane and 
mediate kinase signals (40). Multiple mechanisms by which the steroid hormone 
receptors interact with and activate Src have been described. ERα interacts directly with 
the SH2 domain of Src protein through its phosphorylated Y537 residue with the help of 
scaffold proteins including MNAR, Shc and PELP1 (41-43). Androgen receptor (AR) 
forms binary complexes with ERα interacts with and activates Src (44). Using co-
immunoprecipitation we showed that ERα and PRs form protein complexes with Src and 
PLCγ through two different mechanisms. Estrogen stimulated PLCγ via enhancing the 
association of ERα with Src and PLCγ, while progesterone induced activation of PLCγ 
through a pre-exist protein complex involving PRs, Src and PLCγ. 
In breast cancers, Src is a crucial protein in a complex interaction network. Crosstalk 
between Src, EGFR and ERα contributes to tamoxifen resistance in breast cancer cells 
and in patients (45, 46). A very recent study revealed that loss of C-terminal Src kinase 
(CSK), a suppressor of Src family kinases, confers endocrine therapy resistance in ER+ 
breast cancer cells (47). Given the importance of Src in ER+ breast cancer cells, ongoing 
clinical trials are exploring combination of Src inhibitors dasatinib and bosutinib with 
endocrine therapies (48). By targeting ERα-Src complex, BHPI distorts the anticipatory 
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UPR pathway and tips the scales from cytoprotective to cytotoxic (49). Instead of blocking 
ERα function, BHPI hyperactivates ERα-Src mediated UPR, induces sustained increase 
of cytosol calcium, toxic protein synthesis inhibition and drastic ATP depletion, leading to 
necrotic cell death. 
  Our work demonstrated that c-Src is the key protein tyrosine kinase mediating 
steroid hormones stimulated UPR activation. In breast cancer cells, overexpressed Src 
facilitates the estrogen and progesterone activated moderate anticipatory UPR which 
protects cells from EnR stress induced apoptosis. BHPI hijacks the ERα-Src-PLCγ protein 
complex and causes strong and sustained UPR activation, resulting in necrotic cell death. 
To survive under lethal hyperactivation of UPR, BHPI resistant cells downregulate Src 
expression and diminish UPR activation. Thus, Src plays a previously undescribed pivotal 
role in activation of the tumor protective anticipatory UPR, thereby increasing the 
resilience of breast cancer cells. This is a new role for Src and the UPR in the pathology 
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